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Abstract 
Introduction: Childhood obesity is a major epidemic for many industrialized countries, 
especially in countries where a high fat diet is prevalent. The purpose of this thesis was to 
examine the effect of obesity and high fat diet on cardiovascular risk factors (e.g. 
xanthine oxidase activity and uric acid formation)  and on small  intestinal drug 
metabolism. 
Methods: An assay measuring the production of 7-hydroxy-lumazine was developed as a 
probe for xanthine oxidase activity. This lumazine assay was used to study xanthine 
oxidase as a risk factor for cardiovascular disease in obese children compared to normal-
weight children, and this assay was also utilized to study xanthine oxidase activity in 
obese adolescents before and after weight loss to determine xanthine oxidase’s role in 
mediating changes in blood pressure due to weight loss. In order to study the effects of 
obesity and high fat diet on small intestinal drug metabolism, UGT activity was assessed 
in a rat model of diet-induced obesity using in vitro phenotyping methodologies. 
Results: Plasma xanthine oxidase activity was increased in obese children and was 
associated with BMI z-score and waist circumference, but was not associated with blood 
pressure. Weight loss via meal replacement therapy led to decreases in both uric acid 
production and excretion, but no significant change in plasma levels. Increases in UGT 
activity were observed in both obesity resistant and obesity prone rats when they were fed 
a high fat diet, even though the obesity resistant rats didn’t gain a significant amount of 
weight when fed a high fat diet. 
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Conclusions: Changes in xanthine oxidase activity and intestinal UGT activity may be 
due to changes to diets and gut microbiota. High fat diets have been shown to alter the 
gut microbiota and increase plasma LPS levels. Therefore, a high fat diet and not obesity 
may be responsible for both the changes in xanthine oxidase and UGT activities, and 
future studies on obesity and CVD risk or alterations in drug metabolizing enzymes 
should focus on monitoring diets and changes to the gut microbiota.  
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1.1 Childhood Obesity 
1.1.1 Prevalence and definition of childhood obesity:  
Childhood obesity is a major epidemic for many industrialized countries. As 
shown in Figure 1.1, childhood obesity in the United States has tripled over the last 3 
decades to a rate of 18%.1 In children, obesity is defined differently as compared to 
obesity in adults. In adults, cut-off values for body mass index (BMI), a ratio of the 
weight (kg) to the height (m2), are used to define obesity. Using these cut-off values, 
adults are classified as normal weight, overweight, or obese (class I-III) according to cut-
off values shown in Table 1.1. On the other hand, obesity in children is defined by the 
percentile of a child’s BMI. A child or adolescent (ages 2-18 years old) is considered 
overweight if they are between the 85th and 95th percentile for children of the same age 
and sex, and a child is considered obese if they are at or above the 95th percentile for 
children of the same age and sex. A chart that is used to calculate the percentile in boys is 
shown in Figure 1.2.  
Table 1.1 Classification of Obesity in Adults: 
BMI Obesity Classification 
19 - 24.9 Normal 
25 – 29.9 Overweight 
30 – 34.9 Class I Obesity 
35 – 39.9 
40 + 
Class II Obesity 
Class III Obesity 
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Figure 1.1 Trends in Obesity Among Children and Adolescents: United States, 1963-
2008  
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Figure 1.2 BMI-for-Age Percentiles in Boys Ages 2-20 Years Old 
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1.1.2 Environmental causes of obesity:  
In general terms, the cause of obesity childhood obesity is an imbalance in caloric 
consumption and insufficient amount of energy expenditure; which ultimately leads to 
increased accumulation of fat or white adipose tissue. Even though the cause of obesity is 
relatively simple, many factors influence the accumulation of body fat including various 
environmental and genetic factors. Schools, communities, and homes are all 
environments that influence what children eat and the amount of physical activity they 
participate in. Schools have a major influence on what children eat because most students 
drink beverages and eat meals and snacks while in school, and over half of middle and 
high schools in the U.S. offer less healthy foods that are high in fat or calories and 
beverages that are high in sugar for purchase in vending machines, at school canteens, 
and at events.2 Schools also impact a child’s physical activity via their physical education 
classes, which are important for providing physical activity to children and adolescents. 
However, reports on the physical activity habits of children and adolescents in 2007 and 
2009 (from the Centers for Disease Control and Prevention and the Department of Health 
and Human Services) reported that only 33% of students in the U.S. attended daily 
physical education classes and more than 80% of students in grades 9-12 had less than 60 
minutes of physical activity each day. 3,4 In addition to schools as a factor influencing 
childhood obesity, modern technology and social media negatively impact the obesity 
epidemic by specifically targeting children and adolescents with advertisements and 
marketing of unhealthy foods that are low in nutrients and high in calories, fat, sugar, and 
salt.5 Television viewing not only increases exposure to advertisements of unhealthy 
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foods, it also contributes as a factor for childhood obesity by decreasing the amount of 
time a child can spend doing physical activities and increasing food intake through 
snacking and eating meals in front of the television.6,7 Lastly, geographical communities 
have a large influence on childhood obesity; for example a community with access to a 
supermarket has reduced risk for obesity as compared to communities without access. 
Specifically, families that live in rural, minority, or low-income communities have little 
to no access to supermarkets that sell fruits, vegetables, and other affordable and healthy 
foods which results in increased risk of obesity in these communities.8 The 
aforementioned environmental factors influence obesity to varying degrees and these 
factors may be very hard to target to improve the health of children, but nonetheless these 
factors must be taken into consideration when conducting research on childhood obesity. 
1.1.3 Genetic causes of obesity:  
In addition to the multiple environmental factors that affect obesity, genetics also 
play a role in childhood obesity. Single nucleotide polymorphisms (SNPs) have been 
found by genome-wide association studies to increase an individual’s risk for obesity and 
are associated with either monogenic or polygenic obesity via satiety signaling pathways; 
the most significant SNPs include those found in fat mass and obesity associated gene 
(FTO) and melanocortin 4 receptor (MC4R).9 These two genes are involved in hormonal 
regulation of appetite (Figure 1.3). The arcuate nucleus of the hypothalamus is the major 
site for neuronal signaling for appetite regulating hormones and it is composed of two 
types of neurons. The neurons that express proopiomelanocortin (POMC) and cocaine- 
and amphetamine-regulated transcript (CART) are responsible for the anorexigenic 
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signaling. POMC is precursor protein that is processed in to alpha, beta, and gamma 
melanocortins (also known as melanocyte stimulating hormones or MSH) and 
lipotropins. These anorexic neurons are activated by peptides leptin and glucagon-like 
peptide-1 (GLP-1) which leads to the release of alpha-melanocyte stimulating hormone 
(α-MSH). α-MSH then binds to and activates MC4R on downstream secondary neurons 
in the paraventricular nucleus (PVN) that express thyrotropin-releasing hormone (TRH) 
and corticotropin-releasing hormone (CRH) which mediate the downstream anorexigenic 
effect. In addition to modulating the anorexigenic signaling, leptin and GLP-1 also inhibit 
orexigenic (increases appetite) signaling by inhibiting neurons in the lateral hypothalamic 
area (LHA) of the hypothalamus. The neurons responsible for the orexigenic signaling 
are the neurons that express neuropeptide Y (NPY) and agouti-related peptide (AgRP). 
These orexigenic neurons are stimulated by ghrelin which leads to the release of 
neuropeptide-Y (NPY) and the activation of neuropeptide-Y receptors (Y1R). Activation 
of Y1Rs on neurons in the LHA that express orexin A/B (ORX) and melanin 
concentrating hormone (MCH) mediates the downstream orexigenic effect. NPY also 
activates Y1Rs on neurons that express POMC/CART and neurons in the PVN which 
leads to inhibition of anorexigenic signaling. 
The FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase that 
has an uncertain cellular function, but a SNP within the first intron of FTO (rs9939609) is 
strongly associated with BMI in both children and adults.10-12 The risk allele (A allele) for 
the SNP in FTO is very common and it was found to have an allele frequency of 54 
percent.13 According to Frayling et al., individuals that were homozygous for the A allele 
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of FTO had 1.7-fold increased odds of obesity compared to individuals that were 
homozygous for the low risk T allele.11 One possible mechanism of action of this FTO 
SNP’s obesity risk is regulation of ghrelin, an orexigenic hormone.13 The obesity risk 
allele in FTO has been shown to increase ghrelin mRNA and peptide levels which lead to 
both the inhibition of anorexic signaling and activation of orexigenic signaling.13 
SNPs in MC4R also increase risk for obesity via changes in the hormonal regulation of 
appetite, and loss of function mutations in MC4R are responsible for the majority of 
monogenic obesity cases.14 Hyperphagia is a key feature of MC4R deficiency, and this is 
due to MC4Rs being expressed on neurons in both the PVN and the LHA of the 
hypothalamus. Subsequent stimulation of these receptors leads to activation of anorexic 
signaling and inhibition of orexigenic signaling pathways. Even though MC4R plays a 
major role in appetite suppression, loss of function mutations in MC4R do not necessarily 
lead to obesity. As shown in a longitudinal study by Stutzmann et al., the penetrance of 
obesity in carriers of MC4R mutations is 37% in subjects at 20 year olds, which increases 
to 60% in subjects as they reach ages >40 years old.14 This change in penetrance of 
obesity in MC4R mutation carriers over time shows that environmental factors contribute 
greatly to the development of obesity even in those predisposed to it. 
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Figure 1.3 Hormonal Regulation of Appetite 
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1.1.4 Chronic inflammatory state that occurs in obesity: 
Although there are a multitude of factors that influence the cause of obesity, the 
biological and physical consequences of obesity are relatively consistent. For example, 
obesity is characterized by an abundance of adipose tissue, increased oxidative stress, and 
a low-grade systemic inflammation. These changes in biophysical characteristics are due 
to adipocytes secreting various inflammatory cytokines and adipokines. There are two 
major types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue, 
however, obesity is characterized only by the increase in the former. WAT is the major 
depot for energy storage and it is made up of adipocytes, endothelial cells, fibroblasts, 
leukocytes, and macrophages. Adipocytes are the major secretory cells of WAT and the 
adipokines and inflammatory cytokines that are secreted by WAT include leptin, 
adiponectin, resistin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and 
monocyte chemoattractant protein-1 (MCP-1). Because obesity often results in increased 
amounts of WAT, obese adults and children often have higher levels of adipokines and 
cytokines (Table 1.2). 15,16  
Adipokines are proteins that are mainly produced by adipocytes. Leptin and 
adiponectin are examples of adipokines that have been extensively studied in obesity. 
Leptin’s primary role is to suppress appetite via the signaling pathway shown in Figure 
1.3, and it is positively correlated with adipose tissue mass.17 Leptin has also been shown 
to upregulate adhesion molecules and the production of various cytokines such as TNF-α 
and MCP-1.15 Leptin is so important in the development of obesity that mutations in the 
leptin gene or its receptors in animals serve as obesity models for obesity related 
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research. Adiponectin is primarily produced by adipocytes, but paradoxically its levels do 
not increase in obesity as compared to leptin. Adiponectin is decreased in obesity and 
increased in patients with anorexia nervosa.18,19 Adiponectin has an important role in the 
regulation of cytokines released by adipocytes. For example, there is feedback inhibition 
in which TNF-α levels and activity are reduced by adiponectin, but TNF-α also 
downregulates adiponectin; which would explain why we see both decreased levels of 
adiponectin and increased TNF-α levels in obesity.20,21 Adiponectin is also considered to 
be an anti-inflammatory adipokine due to its inhibition of IL-6 production via inhibition 
of nuclear factor κB (upstream regulator of inflammation), which would partly explain 
why the decrease in adiponectin seen in obesity leads to a chronic inflammatory state.22 
Table 1.2: Plasma levels of Adipokines and Cytokines in obese individuals.15,16 
 
 
 
  
 
 
 
 
 
 
 
*p-value ≤ 0.05 
Variable 
Pediatric Adult 
Control  
(n = 63) 
Obese  
(n = 63) 
Control  
(n = 16) 
Obese 
 (n = 9) 
Leptin (ng/ml) 7.9 ± 5.1 19.9* ± 7.4 7 ± 3 17 ± 2* 
IL - 6 (pg/ml) 13.1 ± 3.9 45.2* ± 11.8 1.2 ± 0.3 2.8 ± 0.5* 
TNF - α (pg/ml) 3.9 ± 1 9.2* ± 2.3 8 ± 1 9.2 ± 1.4 
Resistin (ng/mL) 12.8 ± 8.3 24.6* ±12.9 6.3 ± 0.8 7.8 ± 0.5* 
Adiponectin (µg/mL) 13.3 ± 1.8 8.6* ± 0.8 11 ± 1.8  8.8 ± 1.3 
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1.1.5 Physiological changes due to obesity: 
In conjunction with inflammation, many physical changes also occur in obesity. 
The most obvious physical sign of obesity is size; of which, body surface area (BSA) is a 
unit that is a useful measure to assess size as it increases with weight. The increase in 
BSA with weight has been accurately estimated in obese individuals using multiple 
published formulas (with r2 values between 0.971 and 0.999).23 It has been observed that 
obese individuals have increased cardiac output as compared to non-obese individuals. 
Cardiac output is increased in obesity due to increases in stroke volume and higher heart 
rates, and cardiac output has been accurately predicted in obese populations when BSA is 
factored into calculations.24-26 Cardiac output is an important factor in the renal clearance 
of drugs because an increase in cardiac output also results in a change in kidney function 
due to hyperfiltration. This increase in glomerular filtration due to obesity can be 
accurately predicted in obese adults by various methods such as the modified Cockcroft-
Gault method or the Modification of Diet in Renal Disease method; although currently, 
there are no good prediction equations for estimating kidney function in obese children or 
adolescents.27,28 Surprisingly, even though the obese population has increased cardiac 
output, hepatic and intestinal blood flow have not been shown to differ between lean and 
obese populations.28-30  
1.1.6 The effect of obesity on drug metabolism:  
The major sites of drug metabolism are the liver and the small intestine, and 
although blood flow to the liver and intestine are unchanged, obesity has been shown to 
impact drug metabolism in obese populations.31 Therefore, changes in the expression or 
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activity of drug metabolizing enzymes are attributed to these changes in drug 
metabolism. There is a need to understand the expression and activity of drug 
metabolizing enzymes in the obese population in order to better predict potential adverse 
drug reactions, drug clearance, and drug efficacy. The major families of drug 
metabolizing enzymes are the oxidative cytochrome P450s (CYPs) and the conjugative 
uridine diphosphate glucuronosyltransferases (UGTs). The minor families of drug 
metabolizing enzymes are other oxidative enzymes such as xanthine oxidase, (XO), 
flavin monoxogenases (FMOs), and aldehyde oxidase (AO), and conjugative enzymes 
such as sulphotransferases, N-acetyltransferases and glutathione S-transferases. The 
primary role of these enzymes in drug metabolism is to convert xenobiotics to a more 
polar form so that they can be more easily excreted. In regards to obesity, the expression 
and activity of CYPs in obese populations has been studied extensively. CYPs catalyze 
the oxidation of substrates to make substrates more polar and more readily conjugated. 
The major CYPs that were studied in obese populations are the isoforms CYP1A2, 
CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5. The effect of obesity 
on CYPs is specific to individual isoforms, with a decrease in CYP3A4 activity, an 
increase in CYP2E1 activity, and the effect of obesity on isoforms CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, and CYP2D6 being inconclusive.31 Various probe substrates have 
been used to test for changes in CYP3A4 activity in obese individuals and decreases of 
10-40% have been reported, while increases of 10-140% have been reported for 
CYP2E1.28 The effect of obesity on drug metabolism by CYPs in obese children has not 
been studied as extensively as adults, but one study comparing obese children and non-
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obese children by Chiney et al. reported that there were no differences in the activities of 
CYP1A2, CYP2D6, or CYP3A4 as determined by the metabolism of caffeine and 
dextromethorphan.32 
1.1.7 Drug metabolism by UGTs:  
While the effect of obesity on CYPs has been studied extensively, the effects of 
obesity and high fat diet (HFD) on UGTs and intestinal drug metabolism have been 
neglected. UGTs catalyze the conjugation of glucuronic acid to substrates from uridine 
diphosphate in order to make substrates more polar and more readily excreted. In 
humans, the UGTs are classified into four families: UGT1, UGT2, UGT3 and UGT8, 
with UGT1 and UGT2 being the most important families in drug metabolism. The UGT1 
family consists of UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, 
UGT1A8, UGT1A9, and UGT1A10. The UGT2 family consists of UGT2A1, UGT 2A2, 
UGT2A3, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17, and 
UGT2B28. Transcriptional regulators of UGT expression include the ligand activated 
nuclear receptors Farsenoid X receptor (FXR), peroxisome proliferator-activated receptor 
(PPARα), and nuclear factor (erythroid-derived 2)-like 2 (Nrf2). All three of these 
nuclear receptors have endogenous ligands whose levels are altered in obesity which may 
lead to changes to expression and activity levels. FXR activation is possibly increased in 
obesity as unsaturated fatty acids are ligands for FXR, and obesity due to a high fat diet 
(HFD) may lead to increases in unsaturated fatty acids. Fatty acids are also ligands for 
PPARα, which may have increased activation due to obesity and a HFD increasing fatty 
acid levels in the blood. Increases in oxidative stress due to obesity or a HFD also 
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increases Nrf2 activation, which may lead to changes in the expression of UGTs. Of the 
various UGT1A and UGT2B family members, the following isoforms are expressed in 
the small intestine and play an important role on first-pass drug metabolism: UGT1A1, 
1A3, 1A4, 1A6, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, and 2B15. First-pass metabolism of 
drugs by UGTs in the intestine has been shown to significantly affect drug bioavailability 
and toxicity, and potential changes in intestinal UGT expression or activity due to obesity 
or HFD may contribute to the large inter-individual variability that is seen in UGT 
activity.33 
1.1.8 Disease and hypertension risk associated with childhood obesity:  
Unfortunately, the rise in childhood obesity results in the elevation of concomitant 
disease risk. Obese children have been shown to have increased risk for high blood 
pressure, high cholesterol, impaired glucose tolerance, insulin resistance, type II diabetes, 
breathing problems (eg. sleep apnea and asthma), joint problems, musculokeletal 
discomfort, fatty liver disease, gallstones, gastro-esophageal reflux, and social and 
psychological problems when compared to non-obese children.34-40 Specifically, 
cardiovascular disease (CVD) is a major health problem associated with obesity. CVD is 
a class of diseases that involve the vasculature and the heart, such as coronary artery 
disease, heart disease, or cerebrovascular disease. The majority of CVD is caused by 
hypertension, atherosclerosis, and/or hyperlipidemia. Freedman and others have 
demonstrated that obese children have a 70% chance of having at least 1 CVD risk factor 
and a 39% chance to have 2 CVD risk factors (Figure 1.4).35 These CVD risk factors 
included elevated triglyceride levels, increased low-density lipoprotein (LDL) cholesterol 
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levels, decreased high-density lipoprotein (HDL) cholesterol levels, elevated fasting 
insulin levels, elevated systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
CVD risk in children and adolescents are also defined differently than adults. For 
example, adult hypertension or high blood pressure is defined as a having a SBP ≥ 
140mm Hg or DBP ≥ 90mm Hg, whereas childhood hypertension is defined as being at 
≥95th blood pressure percentiles for a child of the same age, sex, and height. Table 1.3 
defines the cut-off values of pediatric hypertension in children of various ages and height 
percentiles. Hypertension, in both adults and adolescents, is associated with increased 
uric acid, and there have been debates over the last few decades about the role uric acid 
plays in the development of CVD in obesity. 
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Figure 1.4 Prevalence of CVD Risk Factors Across BMI-for-Age Percentiles41 
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Table 1.3 Cut-off Values for Hypertension in Children and Adolescents 
 
1.1.9 Uric Acid’s history as a CVD risk factor:  
In addition to the six previously mentioned CVD risk factors, uric acid has long 
been debated as a CVD risk factor. Uric acid is the final catabolism product of purines in 
humans, and it is produced from the sequential oxidation of hypoxanthine to xanthine and 
from xanthine to uric acid. The enzyme responsible for the oxidation of both 
hypoxanthine and xanthine is xanthine oxidoreductase (XOR). There are two forms of 
XOR: xanthine oxidase and xanthine dehydrogenase (further information on XOR will be 
presented in section 1.2.1 Xanthine oxidoreductase).42 Uric acid, which is not further 
metabolized in humans, is excreted primarily via the kidneys. Uric acid was first 
hypothesized to be associated with hypertension in the late 1800’s, and an increase in the 
prevalence of hypertension and CVD in obesity could be due to increases in xanthine 
oxidase activity and plasma uric acid, as it has been shown that uric acid levels increase 
with obesity. During the past 50 years, over 50 epidemiologic studies have shown that 
uric acid levels were associated with, hypertension, or CVD risk43, but most investigators 
concluded that uric acid was just a surrogate marker for obesity, diabetes, or chronic 
Age, y 
95th BP Percentile for Girls, 
mm Hg 
95th BP Percentile for Boys, 
mm Hg 
50th Height 
Percentile 
75th Height 
Percentile 
50th Height 
Percentile 
75th Height 
Percentile 
1 104/58 105/59 103/56 104/58 
6 111/74 113/74 114/74 115/75 
12 123/80 124/81 123/81 125/82 
17 129/84 130/85 136/87 138/87 
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kidney disease (CKD) due to two major factors. The first factor was that the link between 
uric acid and CVD was not always independent of confounding factors such as 
hypertension, diabetes, or renal disease, and the second factor was that there was no clear 
physiological mechanism to link uric acid with CVD or hypertension. Many of the 
confounding factors listed previously develop with age; therefore a way to minimize 
these confounders is to study the uric acid-CVD relationship in younger populations. The 
link between uric acid and CVD is particularly strong in young populations; for example, 
in an evaluation of young adults in the Israeli armed forces, it was shown that those in the 
highest tertile of uric acid levels had a two-fold increased risk for developing 
hypertension within five years.44 Similar results were found across several racial groups, 
including African Americans45 and Japanese46, and a strong link between uric acid and 
hypertension was also found in children/adolescents47. However, in older populations, the 
uric acid-CVD relationship is more variable and conflicting.48,49 The decrease in the 
strength of the uric acid-CVD relationship with age would indicate that a physiological 
mechanism that links uric acid and CVD likely changes over time in an individual. 
1.1.10 Physiological mechanism linking uric acid and hypertension via animal 
models of mild hyperuricemia:  
In order to determine the mechanism linking uric acid to CVD and hypertension, 
investigators studied hyperuricemia in rats. Unlike humans, where uric acid is the final 
catabolism product of purines; rats, mice, and other animals have the enzyme uricase, 
which further metabolizes uric acid to allantoin. Many researchers have induced severe 
hyperuricemia in animals by feeding them uric acid supplements along with the uricase 
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inhibitor oxonic acid. For example, Stavric et al. found that supplementing rats with both 
uric acid and oxonic acid increased serum uric acid levels by 6- to 10-fold, which led to 
acute renal failure due to obstruction of renal tubules by urate crystals.50 This model of 
severe hyperuricemia was useful for studying acute urate nephropathy syndrome 
observed in cancer patients experiencing tumor lysis syndrome, but this model was 
inappropriate for studying the chronic damage of milder hyperuricemia seen in the obese 
population or those with CVD. Mazzali et al. developed a mild hyperuricemia model in 
rats by feeding them a diet supplemented with 2% oxonic acid without adding any uric 
acid.51,52 Mild hyperuricemia (no urate crystal formation in renal tubules) was achieved 
with a 40-100% increase in serum uric acid in their rats. Mazzali et al. recorded a 
significant increase in blood pressure after their rats were fed oxonic acid for seven 
weeks (>30 mm Hg increase) and they also found that there was a significant positive 
correlation between uric acid levels and systolic blood pressure (SBP), with r=0.75, 
which was due to the induction of the renin-angiotensin system (RAS) and the inhibition 
of intrarenal nitric oxide synthase (NOS).51 The same research group also found that mild 
hyperuricemia induced renal arteriolopathy by inducing the renin-angiotensin system 
(RAS), along with interstitial fibrosis, macrophage infiltration, and afferent arteriolar 
thickening.51,52  
1.1.11 Drugs used to lower uric acid: 
 Increases in uric acid levels in obesity may be associated with CVD risk, which 
makes uric acid a target for pharmacotherapy to reduce an obese individual’s risk. 
Currently, there are three major drugs in the United States that are primarily used to 
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lower uric acid levels: allopurinol, febuxostat, and probenecid (Figure 1.5). Allopurinol 
is a purine analog that competitively inhibits XO, but the major inhibitory effect can be 
attributed to allopurinol’s active metabolite, oxypurinol. Allopurinol is also metabolized 
by XO to produce oxypurinol, which acts as an irreversible inhibitor by binding to the 
molybdopterin active site of XO. Febuxostat is a non-purine selective inhibitor of both 
XO and XDH. And lastly, probenecid is a uricosuric drug that competitively blocks the 
reabsorption of uric acid by inhibiting organic anion transporters, including solute carrier 
family 22 member 12 (SLC22A12 or URAT1).  
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Figure 1.5 Structures of Urate Reducing Drugs 
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1.1.12 Pharmacological interventions in animal models to reverse hypertension and 
kidney damage due to hyperuricemia: 
One method to demonstrate that uric acid is mechanistically linked to CVD and 
hypertension is to reverse these cardiovascular effects by lowering uric acid using various 
pharmacological interventions. For example, pharmacological interventions were tested 
to reverse both hypertension and kidney damage by Mazzali et al. caused by 
hyperuricemia in their rat model of hyperuricemia.51,52 Mazzalie et al. reported that 
reducing uric acid via the inhibition of uric acid production due to the addition of 
allopurinol (xanthine oxidase inhibitor), or increasing uric acid clearance via the addition 
of benziodarone (uricosuric agent no longer used in humans) led to normalization of 
blood pressure in their mild hyperuricemic rat model. Blocking the production of uric 
acid or increasing its clearance both negated the effect of oxonic acid on blood pressure, 
which indicates that increased plasma uric acid levels are responsible for the increase in 
blood pressure seen in hyperuricemic rat models. In addition to modifying uric acid 
levels, Mazzali et al. also determined the effect of administering enalapril (an 
angiotensin-converting-enzyme (ACE) inhibitor) or losartan (an angiotensin II receptor 
blocker). Both enalapril and losartan prevented the increase in blood pressure and 
damage to the kidneys due to the addition of oxonic acid to the diet; and it can be 
concluded that the increase in blood pressure and kidney damage from mild 
hyperuricemia is attributed to the induction of the renin-angiotensin system (RAS).52 The 
link between uric acid and hypertension and kidney damage lead to a two-phase 
mechanism for the modulation of blood pressure.43 The first phase of blood pressure 
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modulation is uric acid dependent, whereby uric acid induces the RAS, which leads to 
acute vasoconstriction and ultimately renal arteriolopathy. The second phase, due to the 
kidney damage, results in chronic hypertension and is uric acid independent and sodium 
dependent. This two-phase mechanism explains the discrepancy between uric acid and 
blood pressure that is observed in a young population versus an older population, and it 
also explains why uric acid could not be shown to be independent of hypertension or 
chronic kidney disease (CKD). With a plausible mechanism linking uric acid levels with 
hypertension, uric acid must be reevaluated as a CVD risk factor. 
1.2 Xanthine Oxidoreductase as a Risk Factor for CVD in Obesity 
1.2.1 Xanthine oxidoreductase: 
With uric acid reestablished as a CVD risk factor, the production of uric acid may 
be responsible for the increased uric acid levels seen in obesity. Therefore, xanthine 
oxidoreductase (XOR), the source of uric acid production, must be evaluated as a CVD 
risk factor in obesity. As stated previously, XOR is an enzyme which produces uric acid 
via the subsequent oxidation of hypoxanthine to xanthine and xanthine to uric acid. In 
addition to the production of uric acid, XOR is responsible for a variety of roles in the 
body. In the regulation of nucleic acid turnover, XOR produces irreversible metabolites 
from purines which block the recovery of nucleotides through the purine salvage 
pathway. Another role that XOR is involved in is the production of reactive oxygen 
species (ROS), which may contribute to cardiovascular risk. When oxygen is the electron 
acceptor for a reaction involving XOR, the reactive oxygen species superoxide and 
hydrogen peroxide are formed as byproducts of the XOR catalyzed reaction.53,54 These 
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ROS are responsible for the oxidative damage that is seen in ischemia-reperfusion injury 
and they may contribute to CVD risk in obesity. Lastly XOR catalyzes the metabolism of 
multiple xenobiotics, which include antivirals and anti-cancer agents.55 The numerous 
effects XOR has on CVD risk, drug metabolism, and on other pathways makes XOR a 
pertinent enzyme to study in relation to obesity. 
1.2.2 Expression and organ distribution of xanthine oxidoreductase:  
In humans, XOR can be found in multiple organs, but the liver and intestine have 
the highest transcription levels and activity of XOR.42 XOR is present in two inter-
convertible forms: xanthine dehydrogenase (XDH) and xanthine oxidase (XO).56 XOR is 
expressed as XDH, which can then be converted to XO via oxidation (reversible) or 
proteolysis (irreversible). XOR is considered as a cytosolic enzyme and is highly 
abundant in the cytosol, but it has also been to be associated with the cellular membrane 
and intracellular organelles, such as peroxisomes.57 In addition to being expressed in 
organs, XOR can also be found in biological fluids including blood and milk.56,58 
Circulating XOR in the blood is quickly converted to its XO form, which then attaches to 
and is endocytosed by the vasculature and organs that have low or no expression of 
XOR.59 The circulating XO is able to attach to vascular cells and insert into organs due to 
its ability to bind to sulphated glycosaminoglycans expressed on the endothelial cell 
surface of the vasculature and various organs.60 Circulating XO would explain why XOR 
activity can be found in some organs that show no expression of XOR. The activity of 
circulating XO is particularly intriguing to study in obesity as XO activity in the 
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blood/plasma is much easier to measure clinically, than measuring XO activity in the 
liver. 
1.2.3 Molecular and catalytic structure of xanthine oxidoreductase:  
 As mentioned previously, XOR has two forms in XO and XDH, but the 
components that make up XOR are the same in both forms. The XOR enzyme is a 
homodimer (approximately 145 kDa), and each subunit consists of a molybdopterin 
domain, a flavin adenine dinucleotide (FAD) binding domain, and two iron-sulphur redox 
centers. For a substrate to be oxidized by XOR, the enzyme goes through a two-step 
reaction (Figure 1.6). During the reductive half reaction, substrates bind to the 
molybdopterin domain of XOR, where XOR oxidizes the substrate and XOR 
consequently gets reduced. In the oxidative half reaction, XOR reduces an electron 
acceptor bound to the FAD-binding domain and the XOR itself gets oxidized. The 
electron acceptors for the XDH form can be either NAD+ or O2, but for the XO form, O2 
is the only electron acceptor. During the oxidative half reaction, the ROS superoxide 
anion and hydrogen peroxide are formed from the reduction of O2. Superoxide anion 
produced from circulating XO will react with and reduce the levels of nitric oxide (a 
potent vasodilator) by forming peroxynitrite. Therefore, circulating XO in the plasma 
may lead to endothelial dysfunction and may be a risk factor for CVD risk in obesity. 
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Figure 1.6: Catalysis of Hypoxanthine to Xanthine and Xanthine to Uric Acid by 
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1.2.4 Regulation of xanthine oxidoreductase:  
The gene for XOR spans 60kB and is encoded by 36 exons in humans to produce 
an mRNA transcript of 1333 amino acids.61,62 The gene is located on the short arm of 
chromosome 2 p22.61,62 Human XOR has 91% homology to mouse and rat XOR and 50% 
homology to aldehyde oxidase which has a very similar gene structure and is also located 
on chromosome 2.61 XOR is extensively regulated by both transcriptional and post-
transcriptional methods. It should be noted that the expression of XOR in organs such as 
liver and kidney is >100-fold lower in humans compared to mice and rats indicating 
significantly different regulation between species.63 The gene expression of XOR is 
modulated by multiple factors which include diet,64 cytokines,65 lipopolysaccharide 
(LPS),66,67 and oxygen tension.68,69 Schröder et al. reported that in mice fed a high fat 
diet, XOR mRNA and protein expression were increased; although no mechanism was 
proposed as the cause of this increase. A second factor that influences XOR expression 
are cytokines, and the inflammatory markers and cytokines IL-6 and TNF-α have been 
shown to induce XOR mRNA expression as well as increase XOR activity in bovine 
renal epithelial cells and in human bronchial epithelial cells.62,65 This increase in XOR 
expression is likely due to a decrease in the repression of XOR by the tumor suppressing 
protein scaffold attachment factor B1 (SAFB1) due to the IL-6 phosphorylating SAFB1, 
which leads to increases in XOR expression and activity.62,70 Another factor that 
regulates XOR expression is plasma LPS levels (generated by bacteria in the gut).  
Kurosaki et al. reported that in mice exposed to LPS, XOR expression in various organs 
and tissues was induced.67 A high fat diet, which is common in childhood obesity, has 
 28 
 
been shown to increase LPS levels by altering the gut microbiota to express more gram 
negative bacteria.71,72 Lastly, changes in oxygen tension signaling also alter XOR 
expression or activity in obesity. Lanzillo et al. and Terada et al. have reported that XO is 
regulated by oxygen tension by studying XO activity and messenger RNA expression in 
hypoxic and hyperoxic environments.68,69 Terada et al. reported increases in XO activity 
after 24 hours of exposure to hypoxia and a decrease in in XO activity after 24 hours of 
hyperoxia, but they noted that mRNA expression of xanthine oxidoreductase was 
unchanged until 48 hours of exposure to either hypoxia or hyperoxia.68 Those changes in 
XO activity before changes in protein expression occur suggests that XO is regulated 
both pre- and post-translationally by oxygen tension. As mentioned before, obesity is 
characterized by inflammation and oxidative stress, which increases the amount of ROS 
in obesity. ROS are important mediators of oxygen tension signaling (involved in 
hypoxia inducible factor 1-alpha stabilization, plasminogen activator inhibitor-1 
induction, and others), which may lead to changes in the expression and activity of XOR 
due to the fact that XOR has a hypoxia inducible factor binding site in its promoter 
region.62,73  
1.2.5 Uric acid excretion: 
In addition to the production of uric acid by XOR, uric acid excretion by the 
kidneys plays a major role in the regulation of plasma uric acid levels. Uric acid excretion 
is via the kidneys is modulated by three factors: glomerular filtration rate, secretion, and 
reabsorption. Glomerular filtration rates (GFR) are known to scale with body size 
descriptors such as weight, BMI, and BSA, which leads to increased GFR in obesity. 
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Secretion of uric acid is mediated mainly by the adenosine triphosphate-binding cassette 
transporter 2, ABCG2, and the sodium-phosphate co-transporters NPT1 and NPT4.74,75 
Lastly, reabsorption of uric acid is mediated by the organic anion transporter URAT1 and 
the solute carrier family 2, GLUT9. Both secretion and reabsorption of uric acid occurs at 
the proximal tube of the nephron, and the dominant mode of urate transport is 
reabsorption; with an average of only 5-10% of filtered urate actually being excreted into 
the urine.74 However, the renal proximal tube tubule can dramatically increase its 
reabsorption capacity such that the fractional excretion of urate is nearly constant even 
with dramatic changes in urate concentrations; for example, when compared to healthy 
individuals, gout patients with nearly twice the concentration of urate in the blood had 
similar fractional excretion rates of urate between 5% and 7%.75 Therefore, changes in 
uric acid excretion must be accounted for when examining the relationship between 
obesity, uric acid, and hypertension. 
1.3 Methods to Study Obesity and its Consequences 
1.3.1 Treatments and weight loss methods to study obesity’s effect on XO activity 
and uric acid levels: 
Weight loss has always been the recommendation to obese populations to reduce 
CVD risk associated with obesity, and studying the effect of weight loss on XO activity, 
uric acid, and blood pressure will give us greater insight into the mechanism of how 
obesity increases cardiovascular risk. Weight loss can be achieved in a variety of ways; 
including diet modification, pharmacological intervention, or bariatric surgery. Diet 
intervention via meal replacement therapy (MRT) has been shown to be effective at 
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moderately reducing weight in both obese adolescents and adults in a short period of time 
leading to reductions in weight varying from 5-10% after 2-4 months.76,77 Orlistat is the 
only approved pharmacological intervention for weight loss in adolescents. Orlistat 
works by inhibiting intestinal lipases which blocks the digestion of triglycerides into free 
fatty acids. Only digested triglycerides can be absorbed by the intestine, which leads to a 
calorie deficit. Orlistat does however have notable side effects and its limited efficacy 
impedes its use clinically in children. Bariatric surgery, such as Roux-En-Y gastric 
bypass (RYGB) surgery has been shown to be safe and it has been shown to reduce 
weight in severely obese adolescents by an average of 70% at one year post surgery.78 
RYGB is a common bariatric surgery that is effective at reducing weight that also has a 
good safety record.79,80 RYGB is a procedure that is defined as both restrictive and 
metabolic. RYGB involves separating the stomach into a small pocket in the upper 
stomach that is connected to a roux jejunal limb (restrictive change) and the rest of the 
stomach is still attached to the biliary limb (metabolic change). Restrictive surgeries limit 
the rate of food intake to aid in weight loss; while metabolic procedures alter bile flow 
which leads to less absorption of fatty acids. Changes in the bile flow after RYGB has 
been shown to alter the gut microbiota, and this change is likely due to changes in the 
amount of free bile acids in the intestinal tract. In the normal enterohepatic circulation, 
conjugated bile acids are secreted into the duodenum to mix with fatty acids to aid in 
their digestion, and any free bile acids are then reabsorbed in the ileum. After RYGB 
serum bile acids increase and this is attributed to the fact that bile acids and food have 
less time to mix and more free bile acids are reabsorbed at the ileum.81 More free bile 
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acids will select for bile-tolerant bacteria such as the gram negative proteobacteria,82 
which may lead to alterations on LPS levels, XOR expression, and drug metabolism. 
1.3.2 Animal models of obesity to study changes in drug metabolism: 
Initial studies on the effect of obesity and HFD on liver-mediated drug 
metabolism were done in animal models of obesity. In the case of intestinal drug 
metabolism by UGTs, animal models would also be ideal for initial studies as many of 
the confounding factors from human studies of obesity are eliminated. There are two 
major types of animal models of obesity: genetic models of obesity and diet-induced 
models of obesity. These models of obesity are from mice and rats, which have 
neurotransmitters and peptides that regulate food intake and satiety that are similar to a 
human’s hormonal control of appetite that was previously described.83 The genetic 
models of obesity that are most prevalent are due to single point mutations leading to a 
loss of leptin or loss of leptin receptor activity; which leads animals to overeat and 
become overweight within weeks after birth. The major concern with studying obesity in 
models which lack leptin activity is that obesity in humans is rarely caused a loss in leptin 
activity, and in fact an increase in leptin is characteristic of human obesity.84 
Diet induced models of obesity are more similar to human obesity than genetic models of 
obesity, and they lead to clinical symptoms that are also present in human obesity such as 
insulin resistance, elevated cholesterol, elevated triglycerides, and elevated plasma leptin 
levels when compared with controls on a standard diet. Diet-induced models of obesity 
are achieved by allowing normal-weight animals free access to high fat diets (HFDs), 
which contain similar amounts of fat content contained in modern western diets. Diet 
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induced models of obesity also take longer to develop than genetic models; usually 12-16 
weeks of a HFD before significant weight gain is achieved in rats.83 HFDs have also been 
shown to increase LPS production and penetration into the body due to changes in the gut 
microbiota, which may ultimately lead to changes in XOR and UGT expression or 
activity via an increase in oxidative stress.71,72 
1.4 Summary: 
Obesity and a high fat diet are associated with increases in various CVD risk 
factors, such as hypertension. Hypertension in obesity may be caused by increases in uric 
acid and XO activity, as a plausible mechanism linking uric acid and blood pressure has 
been discovered. Alterations in obese populations in the production of uric acid by XO or 
changes in uric acid excretion may be underlying changes in uric acid levels and 
ultimately blood pressure. In addition to increased risk for CVD risk factors, drug 
metabolism may be altered in the small intestine of obese individuals. Therefore, the 
following research objectives are presented to study XO and uric acid as CVD risk 
factors in childhood obesity and changes to intestinal UGT activity in obesity. 
1.5 Research Objectives: 
1. Develop a sensitive assay to quantitate plasma xanthine oxidase activity 
An assay capable of measuring XO activity in plasma would allow for easy measurement 
of uric acid production in children. 
2. Determine if obesity is associated with plasma xanthine oxidase activity and if 
plasma xanthine oxidase activity is correlated with cardiovascular disease risk 
factors. 
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Uric acid has long been considered as a CVD risk factor, but XO activity has not been 
studied as a possible risk factor for CVD in obesity. Therefore, the purpose of this study 
was to determine if the production of uric acid via XO activity is associated with obesity. 
3. Evaluate the effects of weight loss on plasma xanthine oxidase activity, uric acid 
clearance, traditional CVD risk factors, cytokine levels, and creatinine clearance. 
The purpose of this study was to determine the mechanism(s) of how obesity and weight 
loss alters cardiovascular risk. 
4. Develop assays to probe for UGT inhibition. 
Specific inhibitors of UGTs are needed in order to determine substrate specificity for 
UGT isoforms, which will allow for more detailed studies on UGTs in areas such as 
obesity. 
5. Determine alterations in intestinal UGT activity by obesity and high fat diet in 
animal models of obesity. 
The purpose of this study was to evaluate the changes in drug metabolism enzyme 
activity in rat models of obesity with a purpose of identifying the feasibility of using 
these animal models of obesity as predictors of changes in clearance in obese humans.  
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Chapter II 
Lumazine as a Highly Sensitive and Specific Probe for Plasma Xanthine Oxidase 
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2.1 Introduction:  
 Xanthine oxidase (XO) is an oxidative enzyme that is responsible for purine 
catabolism, oxidizing hypoxanthine to xanthine and xanthine to uric acid. 85 XO has been 
extensively studied due to its role in producing uric acid and reactive oxygen and 
nitrogen species (RONS).86,87   Both uric acid and RONS have been shown to be 
important regulators of vascular function and dysfunction. Specifically high levels of uric 
acid (hyperuricemia) has been implicated as a risk factor for hypertension 43, 
cardiovascular disease (CVD) 88,89, and chronic kidney disease (CKD). 90 RONS play an 
important role in ischemia-reperfusion injury and regulation of redox-sensitive 
transcription factors that can affect angiogenesis.91,92 Because XO is a key component to 
vascular health, it is an attractive biomarker candidate for vascular health and disease. 
An accurate method to measure XO activity that is both fast and easy would be essential 
to determining if XO would serve as an ideal candidate biomarker for vascular health and 
disease. XO is found in the epithelium of many tissues, but more highly expressed in the 
liver and intestines.93-95 Therefore, measuring XO activity from the liver cytosol is an 
option, as activity would be high. Chiney et al. and others have measured xanthine 
oxidase activity with caffeine as a probe substrate for in vivo phenotyping.96,97 Despite 
the robustness of in vivo phenotyping, these methodologies are difficult, costly, and time 
consuming; and therefore, would not be an appropriate methodology to measure XO 
activity rapidly. Alternatively, XO is also present in plasma.58,98  Measuring XO activity 
from the plasma may be a better option, however there are still some challenges as 
plasma XO activity is not as robust as XO activity in the liver.58,99,100.   
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The gold standard or conventional method to measure XO activity is to quantify 
the conversion of hypoxanthine to xanthine or xanthine to uric acid (Scheme 2.1). 
However, measuring uric acid production in human plasma is challenging because; 1) 
human plasma contains varying amounts of endogenous uric acid, 2) uric acid has poor 
solubility in water which leads to precipitation of analytical standards, and 3) analytical 
analysis of uric acid via HPLC+UV detection are not sensitive enough to quantify XO 
activity in human plasma. Thus an alternative method of measuring XO activity is with a 
commercially available XO kit.  Commercial XO fluorometric assay kits are available 
(e.g. Cayman 10010895).  According to the manufacturer’s description, “The assay is 
based on a multistep enzymatic reaction whose end product resorufin, a highly 
fluorescent compound, can be easily analyzed using an excitation wavelength of 520-550 
nm and an emission wavelength of 585-595 nm”. XO activity assay kits indirectly 
measure XO activity by measuring the hydrogen peroxide byproduct of XO metabolism. 
Unfortunately, many kits are not sensitive enough to detect plasma XO activity in most 
healthy individuals, but could potentially detect plasma XO activity when it is increased 
in certain disease states. However, during an initial evaluation of this kit for measuring 
XO activity in plasma, we observed lack of inhibition by allopurinol, a selective XO 
inhibitor, indicating that the assay was not selective for XO.  Therefore, the aim of this 
study was to develop a highly sensitive and specific method to measure plasma XO 
activity in humans and to compare this method to conventional and alternative methods 
of measuring plasma XO activity. 
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To alleviate some of the challenges to measuring XO activity in plasma, we utilized 
lumazine, a fluorescent pteridine that is a highly selective substrate for XO, and measured 
the conversion of lumazine to 7-OH lumazine 101,102 (Scheme 2.1.).   The advantages of 
measuring 7-OH-lumazine production instead of uric acid production are 1) 7-OH-
lumazine is not found in plasma endogenously, 2) the high water solubility of 7-OH-
lumazine, and 3) 7-OH-lumazine is a highly fluorescent compound resulting in more 
sensitive method than a xanthine-based assay with a UV detector.  Therefore we now 
describe an accurate, sensitive and specific methodology for quantifying XO activity in 
plasma to determine if plasma activity is a biomarker for vascular health and oxidative 
stress. 
2.2 Methods: 
Supplies and Chemicals 
Lumazine, xanthine, uric acid, chromatographically purified xanthine oxidase 
from bovine milk (Grade I, suspension in 2.3M (NH4)2SO4, containing 1 mM Na 
salicylate, Cat # X1875) , allopurinol, and pooled human liver cytosol were obtained 
from Sigma (St. Louis, MO, USA). Oxypurinol was obtained from Toronto Research 
Chemicals (North York, ON, Canada). Strata-X 33µ polymeric reversed phase filters 
were obtained from Phenomenex (Torrance, CA, USA). Nanosep 30k Omega filters were 
from Pall Life Sciences (Port Washington, NY, USA). Xanthine Oxidase Assay Kit (Cat 
# 10010895, Cayman Chemical Company, Ann Arbor, MI, USA). Rat plasma was 
obtained from BioreclamationIVT (New York, USA).  This study was approved by the 
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University of Minnesota IRB Board (IRB no. 1204M12582) for the assay and method 
development.  
7-OH-lumazine purification method 
To purify 7-OH lumazine, 100mL of 3.3mM lumazine in 5mM potassium 
phosphate buffer pH 7.4 were incubated with 100 Units (~2.2mL) of purified xanthine 
oxidase (XO) from bovine buttermilk for 5.5h at 37°C to produce 7-OH-lumazine. The 
reaction was stopped by addition of 200mL ice-cold methanol. Incubation mixture was 
then centrifuged at 10,000 x g for 10 min at 4°C. Supernatant was then saved and dried. 
Subsequently the sample was reconstituted in mobile phase (99:1 25mM ammonium 
acetate pH 4.7:acetonitrile) and injected into the preparatory HPLC system to separate 7-
OH-lumazine from lumazine. The preparatory HPLC system used to purify 7-OH-
lumazine consisted of a SCL-10A HPLC controller,  a SIL-10A autosampler,  LC-10AD  
pumps, (Shimadzu, Columbia, MD), a SpectraFOCUS forward optical scanning UV 
detector (Spectra-Physics, Santa Clara, CA, USA), and a HAISIL HL C18 5uM 
100x20mm column (Higgins Analytical Inc., Mountain View, CA, USA). The isocratic 
gradient used was 99:1 25mM ammonium acetate pH 4.7 acetonitrile at 5 mL/min. 7-OH-
lumazine was collected and lyophilized after separation. 7-OH-lumazine metabolite was 
confirmed via mass spectrometry and NMR spectroscopy (Supplemental Figure 2.1). 
Measuring XO Activity With and Without Inhibitors Using Xanthine Oxidase Assay 
Kit 
XO activity in plasma and liver cytosol was measured per manufacturers’ 
directions; in short, 50 µL of assay cocktail was mixed with 40 µL of human/rat plasma 
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(undiluted) or liver cytosol (100x/1000x diluted with kit’s sample buffer) with the 
addition of 10 µL of sample buffer or inhibitor. Only plasma samples with detectable XO 
activity were used and incubated with inhibitors. Final inhibitor concentrations of 50µM 
allopurinol and oxypurinol were used in these experiments. Boiled samples were also 
used as a negative control (boiled plasma samples were reconstituted with an equal 
volume of sample buffer provided in the kit). Samples were incubated for 45 minutes at 
37°C and then fluorescence was measured at the following wavelengths: 
Excitation=530nm and Emission=590nm. All samples were run in triplicate. 
Production of 7-OH lumazine compared to uric acid production 
Partially-purified XO (0.28, 0.56, 1.13, 2.25, 4.5, 9, 18 mUnits/mL final 
concentration) was incubated with 25mM xanthine in 50mM potassium phosphate buffer 
pH 7.4 for 20 minutes (100 µL total incubation volume) in triplicate. Incubations were 
flash frozen to terminate the incubation. 200 µL of 250µM caffeine (internal standard) in 
water was added to the incubations and incubations were then thawed on ice. Samples 
were then filtered using 30K MWCO filters. Uric acid production was measured with the 
following HPLC system: Waters 2695 HPLC (Milford, MA, USA), Waters 2487 dual 
absorbance detector (Milford, MA, USA), and a Synergi 4u 200x4.6mm Polar-RP 80A 
column (Phenomenex, Torrance, CA, USA). The protein-free samples were then injected 
into the analytical HPLC system and absorbance was measured at a wavelength of 
292nm. The gradient used is listed in Supplemental Table 2.1. Purified XO (0.28, 0.56, 
1.13, 2.25, 4.5, 9, 18 mUnits/mL final concentration) was also incubated in triplicate with 
40µM lumazine in 50mM potassium phosphate buffer, pH 7.4 for 10 min (200 µL total 
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incubation volume). Uric acid production (ng/min) was then plotted against 7-OH-
lumazine production (ng/min). 
Kinetics of Lumazine Metabolism 
The enzyme kinetics for lumazine metabolism were determined by incubating 
1.8mUnits/mL of partially-purified bovine XO with 45, 15, 5, 1.67, 0.556, 0.185, and 
0.062 µM of lumazine with and without the addition of allopurinol (50µM final 
concentration) or uric acid (80µM final concentration)in 50mM phosphate buffer, pH 7.4. 
Reaction mixtures (200 µL total volume) were incubated at 37°C for 5 min. 
Measuring XO Activity With or Without Inhibitors Using Lumazine as a Probe 
Substrate 
XO activity was determined by incubating lumazine (40µM final concentration) 
with 100 µL of human/rat plasma (undiluted) or liver cytosol (100x/1000x diluted with 
50mM potassium phosphate buffer, pH 7.4) with the addition of 20 µL of buffer or 
inhibitor in triplicate. Final inhibitor concentrations of 50µM were used for allopurinol 
and oxypurinol, and 80µM of uric acid was also tested for inhibition. Reaction mixtures 
(200 µL total volume) were incubated at 37°C for 3 hours (plasma) or 5 minutes 
(cytosol).  
Sample Preparation and HPLC Method for 7-OH-lumazine Quantification 
Reactions were stopped and proteins were precipitated by the addition of 2x 
incubation volume (400 µL) of 771nM umbelliferone in ice-cold methanol (internal 
standard). After centrifugation at 10000g for 10 min at 4°C, the supernatants were passed 
through Strata-X 33µ polymeric solid-phase extraction cartridges. The flow-through was 
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saved for HPLC analysis of 7-OH-lumazine. The analytical HPLC system consisted of an 
Agilent 1100 HPLC (Agilent, Santa Clara, CA, USA), a Jasco FP-920 fluorescence 
detector (Jasco, Easton, MD, USA), and a Synergi 4u 200x4.6mm Polar-RP 80A column 
(Phenomenex, Torrance, CA, USA). 50µL of flow-through was injected into the 
analytical HPLC system and fluorescence was measured at the following wavelengths: 
Excitation=340nm and Emission=400nm. The gradient used is listed in Supplemental 
Table 2.2.  
Statistics 
A Student’s t-test was used to determine significance of differences in xanthine 
oxidase activity between control and incubations with inhibitors. P-values < 0.05 were 
considered statistically significant.  All values are expressed as mean ± SD unless stated 
otherwise. 
2.3 Results: 
Inhibition of Cytosolic and Plasma XO Determined by Xanthine Oxidase Assay Kit 
The XO specific inhibitors allopurinol and oxypurinol were both effective at 
inhibiting XO activity in rat liver cytosol, showing >80% inhibition. However, little 
allopurinol and oxypurinol inhibition was observed in human liver cytosol, with 11% (p-
value=0.01) and 15% (p-value<0.01) inhibition, respectively (Figure 2.1). Boiling the 
cytosolic samples had similar effects in inhibiting XO activity in both human and rat 
cytosol, resulting in only 65% (p-value<0.01) and 71% (p-value<0.01) inhibition, 
respectively.  As shown in Figure 2.2, allopurinol and oxypurinol inhibited XO activity in 
rat plasma by 49% (p-value<0.01) and 50% (p-value<0.01) respectively; whereas 
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allopurinol and oxypurinol were ineffective at inhibiting XO activity in human plasma (0-
35% inhibition). Boiling plasma samples had varying effects ranging from 85% inhibition 
in rat plasma (p-value<0.01) to no change in human plasma 1 (p-value=0.16) and 49% 
activation in human plasma 2 (p-value<0.01). 
Lumazine as a Substrate for Bovine Milk Xanthine Oxidase 
7-OH lumazine formation from lumazine, as shown in Figure 2.3, followed 
Michaelis-Menten kinetics with partially purified bovine milk XO with a Vmax= 532 
pmol/min and km= 1.05µM. Allopurinol strongly inhibits lumazine intrinsic clearance 
(Vmax/Km) by 97.8% resulting in a decrease in Vmax to 60 pmol/min (p-value< 0.01) and 
an increase in km 5.36µM (p-value< 0.01). Uric acid slightly inhibits lumazine turnover 
resulting in a decrease in Vmax to 353 pmol/min (p-value= 0.02) but no change to km 
(1.27µM, p-value= 0.36). XO mediated conversion of lumazine to the 7-OH-lumazine 
correlated with XO-mediated conversion of xanthine to uric acid r2 value = 0.99 (Figure 
2.4). 
Inhibition of Cytosolic and Plasma XO Determined by Lumazine Metabolism 
 Allopurinol (50 µM) inhibited XO activity in human liver cytosol by 74% (p-
value<0.01) and rat liver cytosol by 95% (p-value<0.01). (Figure 2.5) Oxypurinol (50 
µM) inhibited XO activity in human liver cytosol by 65% (p-value<0.01) and rat liver 
cytosol by 93% (p-value<0.01). ). Boiling samples inhibited XO activity in human liver 
cytosol by 83% (p-value<0.01) and rat liver cytosol by 95% (p-value<0.01). Uric acid 
increased XO activity in human liver cytosol by 59% (p-value<0.01) and rat liver cytosol 
by 22% (p-value=0.04). However, as shown in Figure 2.6, allopurinol inhibited XO 
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activity in human plasma sample 1 by 87% (p-value<0.01), human plasma sample 2 by 
46% (p-value<0.01), and rat plasma by 98% (p-value<0.01). Oxypurinol inhibited XO 
activity in human plasma sample 1 by 84% (p-value<0.01), human plasma sample 2 by 
48% (p-value=0.02), and rat plasma by 69% (p-value<0.01). ). Boiling samples inhibited 
XO activity in human plasma sample 1 by 91% (p-value<0.01) human plasma sample 2 
by 45% (p-value=0.02) and rat plasma by 99% (p-value<0.01). Uric acid had no 
significant effect on lumazine metabolism by XO in human plasma or rat plasma.  
2.4 Discussion: 
 Xanthine oxidase is an important contributor to hyperuricemia and oxidative 
stress, and may have a role as a risk factor for hypertension, CVD, and CKD. 43,88-90 
Accurate measurement of XO activity is important in determining its role as a possible 
biomarker for vascular health. There are few tools available to easily and accurately 
assess XO activity in human plasma. Therefore, we developed an assay using lumazine as 
a probe substrate and compared it to commercialized XO kits and an assay using xanthine 
as the prototypical substrate for XO. In addition, we also compared the effects of specific 
and non-specific inhibition methods for XO on the metabolism of lumazine and in the 
commercialized kits in order to confirm the specificity of these methods for XO. 
We observed that xanthine oxidase activity was not inhibited in human plasma or 
liver cytosol samples by the selective XO inhibitors allopurinol or oxypurinol when using 
the commercial XO assay (figures 2.1 and 2.2), which would indicate that other enzymes 
besides XO are being measured.  Because there is a differential effectiveness of xanthine 
oxidase inhibitors in rat when compared to human samples, these results demonstrate that 
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the commercialized XO kit is not specific for accurate determination of XO in human 
samples.  One explanation for differential results between species is that the 
commercialized kits use an indirect method of measuring XO activity in multi-step 
enzymatic assay by measuring the production of resorufin from the hydrogen peroxide 
produced by XO. The production of hydrogen peroxide is not specific to XO and other 
enzymes such as semicarbazide-sensitive amine oxidases (SSAO) could be responsible 
for the production of hydrogen peroxide which would interfere with XO assay kits.103 
SSAO activity is higher in humans than in rats, which could explain why this assay was 
more responsive to XO inhibitors in rat samples than compared to human samples.103,104 
The ineffectiveness of XO inhibitors in human samples suggests that the commercialized 
kit may not be measuring XO activity, but instead, it could be measuring the activity of 
other enzymes such as SSAOs. Therefore, kits using hydrogen peroxide as a surrogate for 
XO activity is not an accurate method to quantify XO activity in humans. 
To show that lumazine metabolism is actually due to XO, multiple specific and 
non-specific inhibition methods were tested. The inhibitors allopurinol and oxypurinol 
and boiling samples were almost equally effective at inhibiting XO activity in both 
human and rat liver cytosol or plasma. The specific XO inhibitors inhibiting lumazine 
metabolism to a similar extent as the non-specific method of boiling samples shows that 
lumazine is not metabolized by other enzymes and that it is a specific substrate for XO. 
Recently, Barr et al. found that human liver cytosol usually contains residual oxipurinol 
and sometimes allopurinol, because allopurinol (1 mM) is present in the University of 
Wisconsin cryopreservation solution to prevent reperfusion injury from reactive oxygen 
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species produced by XO (Barr, DMD 2014).105 6-Mercaptopurine, 6-nitroquinazolinone, 
and N-[(2-dimethylamino)ethyl]acridine-4-carboxamide (DACA) were used a probe 
substrates and their metabolites determined by LC-MS/MS. Their studies confirmed that 
XO activity in human liver cytosol is often not measurable, except in cases when 
allopurinol was not present in the perfusate. This may be why we did not observe 
complete inhibition of XO activity in human liver cytosol. 
In order to use lumazine metabolism as a surrogate for xanthine oxidase activity, 
we needed to determine if 7-OH-lumazine production correlated well with the gold 
standard of uric acid production. The linear relationship between lumazine production 
and uric acid production with bovine milk XO indicates that lumazine is a good surrogate 
to measure xanthine oxidase activity instead of measuring overall uric acid production (a 
much less sensitive HPLC-UV method) or with a commercial XO assay kit. Lumazine is 
a more sensitive probe substrate than xanthine, as 2.25 mUnits/mL of XO was producing 
the lowest detectable amounts of uric acid, but 0.28 mUnits/mL of XO was still 
producing detectable amounts of 7-OH-lumazine. The sensitivity of our assay was also 
very high with a limit of detection of 32pg/mL and a limit of quantification of 53pg/mL. 
This higher sensitivity with lumazine allows us to measure XO activity in plasma 
samples or in small samples of human liver (e.g. biopsies) where we could not detect any 
activity using xanthine as a probe substrate.  
The effect of uric acid on lumazine metabolism is something that needs to be 
considered because plasma samples will have endogenous uric acid present at varying 
levels. We see varying effects of uric acid on the metabolism of lumazine based on the 
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matrix and species the XO is derived from. In purified XO from buttermilk, uric acid 
inhibited lumazine metabolism by 34%. This inhibition of bovine XO could be related to 
the inhibition by purines that has previously been reported in bovine XO. 106,107 However, 
in human and rat liver cytosol, we see that the addition of uric acid actually increases 
lumazine metabolism by 59% and 22%. (Figure 2.5) This increase in lumazine 
metabolism could be related to the substrate activation of XO from chicken liver that has 
been previously reported with xanthine as a substrate, in which XO was proposed to have 
multiple substrate binding sites. 108,109 It could be possible that uric acid binds to one 
substrate binding site of XO which leads to changes in xanthine metabolism. In contrast 
to the substrate activation seen in chicken liver XO, a previous study by Tan et al. 
showed that bovine XO added to human plasma is inhibited by uric acid. 110 In our study, 
XO activity in both human and rat plasma showed that uric acid had no effect on 
lumazine metabolism, but endogenous uric acid in human plasma could be masking any 
potential effects of adding uric acid. Human XO has not yet been fully investigated for 
activation or inhibition by purines and the effect of purines on human XO needs further 
investigation. 
In order to show that our lumazine assay is reliable and accurate, we validated our 
assay in four ways: accuracy, precision, linearity, and stability of metabolite. Accuracy is 
the measure of how close a measurement is to its true value and precision is the measure 
of how much variability is in a measurement. Our assay for 7-OH-lumazine is both 
accurate (inter-day and intra-day relative errors of 0-12%) and precise (inter-day and 
intra-day coefficients of variation of 1-12%) as shown in Supplemental Table 2.3. Time 
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linearity of incubations is needed in order to show that the enzyme being investigated is 
not degrading during an incubation, and the metabolism of lumazine to 7-OH-lumazine in 
plasma is linear up to four hours as shown in Supplemental Figure 2.2. Stability of the 
metabolite is needed in order to determine the true activity of an enzyme, as degradation 
or further metabolism of the metabolite will lead to underestimations of enzyme activity. 
7-OH-lumazine is stable in plasma for at least 24 hours at 37°C as shown in 
Supplemental Table 2.4. 
 In conclusion, lumazine is a specific and sensitive probe substrate that correlates 
well with xanthine metabolism which makes it a good substrate to determine plasma XO 
activity. We also show that commercialized XO kits are not accurate for measuring XO 
activity in humans because they use hydrogen peroxide production as a surrogate for XO 
activity, but hydrogen peroxide can be made by enzymes other than XO. With a sensitive 
and specific method to measure plasma XO activity, we can now use this method to 
determine if plasma XO activity would be a good biomarker for cardiovascular health or 
as a risk factor for hypertension, CVD, or CKD. 
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Scheme 2.1 Reactions Used to Measure Xanthine Oxidase Activity 
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Figure 2.1 Cytosolic Xanthine Oxidase Activity Using Xanthine Oxidase Activity Kit 
Human/rat liver cytosol (100x/1000x diluted with sample buffer) was mixed with sample 
buffer or inhibitors (concentrations of 50µM for allopurinol and oxypurinol) and xanthine 
oxidase activity was determined using a xanthine oxidase activity kit. Boiled samples 
were also used as a negative control. All samples were run in triplicate.  
*p-value ≤ 0.05, **p-value ≤ 0.01 
ND = Not Detectable 
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Figure 2.2 Plasma Xanthine Oxidase Activity Using Xanthine Oxidase Activity Kit 
Human/rat plasma was mixed with sample buffer or inhibitors (concentrations of 50µM 
for allopurinol and oxypurinol) and xanthine oxidase activity was determined using a 
xanthine oxidase activity kit. Boiled samples were also used as a negative control (boiled 
samples were reconstituted with an equal volume of sample buffer). All samples were run 
in triplicate.  
*p-value ≤ 0.05, **p-value ≤ 0.01 
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Figure 2.3 Lumazine Kinetics in Purified Bovine Xanthine Oxidase With 
Allopurinol or Uric Acid 
Kinetics of lumazine metabolism was determined by incubating 1.8mUnits/mL purified 
xanthine oxidase with 45, 15, 5, 1.67, 0.556, 0.185, and 0.062 µM of lumazine with and 
without the addition of allopurinol (50µM final concentration) or uric acid (80µM final 
concentration). Compared to control (Vmax= 532 pmol/min and km= 1.05µM) allopurinol 
significantly inhibits lumazine turnover resulting in a decrease in Vmax to 60 pmol/min (p-
value< 0.01) and an increase in km 5.36µM (p-value< 0.01). Uric acid slightly inhibits 
lumazine turnover resulting in a decrease in Vmax to 353 pmol/min (p-value= 0.02) but no 
change to km (1.27µM, p-value= 0.36). 
*significant difference in Vmax (p-value=0.02) 
**significant difference in Vmax and km (p-value<0.01) 
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Figure 2.4 Comparison Between XO Activities as Measured by 7-OH-Lumazine vs. 
Uric Acid Production 
Purified xanthine oxidase (0.28, 0.56, 1.13, 2.25, 4.5, 9, 18 mUnits/mL final 
concentration) was incubated with 25mM xanthine or 40µM lumazine in triplicate. Uric 
acid production (ng/min) was then plotted against 7-OH-lumazine production (ng/min). 
The three lowest concentrations of XO did not produce enough uric acid to be detected 
and were not included in the linear fitting. r2 value = 0.99 
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Figure 2.5 Cytosolic Xanthine Oxidase Activity Using Lumazine as a Probe 
Substrate 
Human/rat liver cytosol (100x/1000x diluted with sample buffer) was mixed with sample 
buffer or inhibitors (concentrations of 50µM for allopurinol and oxypurinol) and xanthine 
oxidase activity was determined using lumazine as a probe substrate. Boiled samples 
were also used as a negative control. All samples were run in triplicate.  
*p-value ≤ 0.05, **p-value ≤ 0.01 
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Figure 2.6 Plasma Xanthine Oxidase Activity Using Lumazine as a Probe Substrate 
Human/rat plasma was mixed with sample buffer or inhibitors (concentrations of 50µM 
for allopurinol and oxypurinol) and xanthine oxidase activity was determined using 
lumazine as a probe substrate. Boiled samples were also used as a negative control 
(boiled samples were reconstituted with an equal volume of sample buffer). All samples 
were run in triplicate.  
*p-value ≤ 0.05, **p-value ≤ 0.01 
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Supplemental material: 
Supplemental Figure 2.1 LC/MS chromatogram of 7-OH-lumazine using 
electrospray ionization in negative mode.  
The most abundant peak shows a mass of 179 g/mol which shows that our compound is 
indeed 7-OH-lumazine. 
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Supplemental Table 2.1 Gradient used for uric acid HPLC assay 
 
Time A (%) B(%) 
0 0 100 
6.5 0 100 
7 30 70 
14 30 70 
14.5 0 100 
18 0 100 
A = Acetonitrile 
B = 97:3 5mM Potassium Phosphate Buffer: Acetonitrile pH=3.0 
 
Supplemental Table 2.2 Gradient used for 7-OH-lumazine HPLC assay 
 
Time A (%) B(%) 
0 95 5 
6.5 95 5 
6.51 50 50 
15.5 50 50 
15.51 95 5 
19 95 5 
A = 25mM Ammonium Actetate pH=4.8 
B = Acetonitrile 
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Supplemental Table 2.3 
Inter-day and intra-day variability for quantification of 7-OH-lumazine in plasma. 
Added 
Concentration 
(pg/ml) 
Intra-day 
Mean 
Measured 
(pg/ml) 
Intra-day 
Precision 
(CV %) 
Accuracy 
(%) 
Relative 
Error % 
156.25 137.42 ±5.2 3.75 87.95 12.05 
625.00 612.45 ±7.1 1.16 97.99 2.01 
2500.00 2496.62 ±118.4 4.74 99.86 0.14 
Added 
Concentration 
(pg/ml) 
Inter-day 
Mean 
Measured 
(pg/ml) 
Inter-day 
Precision 
(CV %) 
Accuracy 
(%) 
Relative 
Error % 
156.25 152.00 ±18.8 12.42 97.28 2.72 
625.00 586.67 ±46.7 7.96 93.87 6.13 
2500.00 2252.63 ±199.3 8.85 90.11 9.89 
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Supplemental Figure 2.2 Time Linearity of 7-OH-Lumazine Production in Plasma 
Two plasma samples were incubated with 40µM lumazine at 37°C for 1, 2, 3, or 4 hours 
in duplicate and the data was linearly fitted. R2=0.98 for both fits below. 
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Supplemental Table 2.4 Stability of 7-OH-lumazine 
Stability of 7-OH-lumazine was tested by incubating standard solutions at 37°C in buffer 
(control), human plasma, or rat plasma for up to 24 hours. Samples were compared to 
standard solution in buffer for zero hours as a control. 
  0 hr 1 hr 2 hr 3 hr 20 hr 24 hr 
Control 100.0% 102.1% 111.6% 101.4% 96.1% 103.8% 
Human 
plasma 93.9% 98.5% 106.4% 105.6% 103.4% 114.6% 
Rat Plasma 98.0% 108.6% 100.1% 107.2% 103.2% 104.1% 
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Chapter III 
Xanthine Oxidase and Cardiovascular Risk in Obese Children 
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3.1 Introduction: 
Obesity rates in the United States among children and adolescents ages 2-19 years 
old have risen nearly 3-fold since 1980; to a rate of nearly 17% in 2010.111 A high rate of 
obesity in children has led to an increased cardiovascular disease (CVD) risk, for 
example, a population based study showed that nearly 70 percent of obese children had at 
least one risk factor for cardiovascular disease.35 The pathological mechanisms of how 
childhood obesity leads to increased risk of CVD are not fully characterized. Oxidative 
stress is one factor that plays an important role in the cardiovascular system and controls 
endothelial function, vascular tone and cardiac function.  The major sources of vascular 
oxidative stress occur through the generation of reactive oxygen species (ROS) by the 
enzymes nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), 
uncoupled nitric oxide synthase (NOS), and xanthine oxidase (XO).112,113 ROS generated 
from XO, such as superoxide anion, are known to affect endothelial function by 
sequestering the endogenous vasodilator nitric oxide (NO). For example, NO-stimulated 
blood flow was increased and endothelial dysfunction was reversed when XO was 
inhibited by allopurinol in adult smokers114 and patients with diabetes115, which shows 
that XO plays a role in CVD in adults. However, little is known about how oxidative 
stress pathways, such as XO, influence cardiovascular risk factors in children.116 The 
primary objective of this study was to determine if plasma XO activity is increased in 
obese children compared to normal weight children. The secondary objective was to 
evaluate if XO activity is associated with CVD risk factors in children by studying the 
correlations between XO activity and CVD risk factors and cytokine levels.  
 62 
 
3.2 Methods: 
This was a cross-sectional study of 42 children and adolescents (mean age = 12 ± 
3 years) from the Minneapolis-St. Paul metropolitan area who were categorized into two 
groups, normal weight and obese, based on age- and sex-specific BMI percentiles.117 
Data were collected between 2007 and 2012.  Normal weight subjects were age- and 
gender-matched, were classified as having a BMI >5th and <85th BMI percentile (n=22), 
and participated in a study evaluating cardiovascular risk factors among families. Obese 
subjects were classified as having a BMI ≥95th BMI percentile (n=20) and were recruited 
from the University of Minnesota Amplatz Children’s Hospital Pediatric Weight 
Management Clinic. The protocol was approved by the University of Minnesota 
Institutional Review Board and consent and assent was obtained from parents and 
participants, respectively.  
Height and weight were obtained using a standard stadiometer and electronic 
scale, respectively, with participants wearing light clothes and no shoes. BMI was 
calculated as weight in kilograms divided by height in meters squared. Waist 
circumference was measured midway between the base of the ribs and the superior iliac 
crest, to the nearest 0.5 cm, taken in duplicate and the mean values were used in the 
analyses. Seated blood pressure was obtained after 5 min of quiet rest, on the right arm 
using an automatic sphygmomanometer. Three consecutive blood pressure measurements 
were taken with a 3 minute rest between. Blood pressure was then averaged. Blood 
samples were collected after a minimum 8-hour fast. Lipids, glucose, and insulin assays 
were conducted with standard procedures at the Fairview Diagnostic Laboratories, 
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Fairview-University Medical Center (Minneapolis, MN), a Centers for Disease Control 
and Prevention–certified laboratory. Homeostasis model assessment-insulin resistance 
(HOMA-IR) was calculated using methods previously described.118 Flow-mediated 
dilation of the brachial artery (FMD) was measured in a subset of the participants (n=16) 
as described previously.119  
Cytokine and oxidative stress markers were measured using a Luminex multiplex 
bead array assay. Measurement of oxidative stress and inflammation blood markers in 
plasma included oxidized LDL (Mercodia, Winston-Salem, NC), C-reactive protein 
(CRP) (Immundiagnostik AG, Bensheim, Germany), interleukin-6 (IL-6) (Quantikine 
HS; R&D Systems, Minneapolis, MN), leptin, monocyte chemotactic protein-1 (MCP-1), 
serpin E1, adiponectin, resistin, and factor D. Plasma was stored frozen at −70 °C until 
assayed at the University of Minnesota Cytokine Reference Laboratory (Clinical 
Laboratory Improvement Amendments licensed) using enzyme-linked immunosorbent 
assay. Oxidized LDL, measured in this fashion, is a reflection of both minimally and 
fully oxidized LDL particles. The intra- and inter-assay coefficients of variation were as 
follows: oxidized LDL 5.5–7.3 and 4.0–6.2, respectively; CRP 5.5–6 and 11.6–13.8, 
respectively; IL-6 6.9–7.8 and 6.5–9.6, respectively. 
Plasma XO activity was determined by measuring the XO-specific conversion of 
lumazine to isoxantholumazine. Briefly, reaction mixtures containing 100µL plasma and 
100 µL of 20µM lumazine in 50mM potassium phosphate buffer (pH=7.4) were 
incubated at 37°C for one hour followed by addition of 200µL methanol (with 
umbelliferone as internal standard) to stop the reaction and remove the proteins. After 
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centrifugation and filtration, the supernatants were saved for HPLC analysis of 
isoxantholumazine. 100 µL of the supernatant was injected onto a 250mm YMC-Pack 
Phenyl column and fluorescence was measured on a Waters 474 Scanning Fluorescence 
Detector set at Excitation wavelength=340nm and Emission wavelength=400nm. One 
Unit of XO activity is defined as the production of one micromole of uric acid per minute 
at 25°C. Xanthine oxidase activity was normalized for total protein in the plasma 
samples. 
Statistical Analyses: Student’s t-test was used to determine the differences 
between obese and normal weight children in regards to plasma XO activity and baseline 
characteristics. Linear regression analysis was used to determine the association between 
plasma XO activity and cardiovascular risk factors, cytokine levels, and oxidative stress 
levels. Data are presented as mean ± standard deviation unless stated otherwise. 
Statistical significance was set at a p-value ≤ 0.05. 
3.3 Results: 
Baseline characteristics are shown in Table 3.1 Compared to normal weight 
children, obese children had higher systolic blood pressure (116±12 vs. 104±10 mmHg, 
p<0.001), total cholesterol (168±25 and 150±27 mg/dL, p=0.03) LDL cholesterol 
(104±20 vs. 85±21 mg/dL, p=0.004), triglycerides (113±57 vs. 62±21 mg/dL, p<0.001) 
and insulin (13±8 vs. 6±1 mU/L, p=0.002), and lower HDL cholesterol (41±9 vs. 53±11 
mg/dL, p<0.001).  
XO was 3.8 fold higher in obese when compared to normal weight children as 
shown in figure 3.1 (118±21 vs. 31±9 nU/mg protein, p<0.001, data is shown in mean ± 
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SEM). FMD was not different between the obese and normal weight children (9.2±2.6 vs. 
10.5±5 %). In a subset of subjects (n=16), plasma cytokine and adipokine levels were 
measured (Table 3.2). Compared to normal weight children, obese children had higher 
leptin (53.3±25 vs. 6.5±5 ng/mL, p<0.01), and lower MCP-1 (80±42 vs. 289±86 pg/mL, 
p<0.01) and serpin E1 (16±20 vs. 103±22 ng/mL, p<0.01), and a trend toward lower 
adiponectin (11.2±3 vs. 16.5±5 µg/mL, p=0.05)(Table 3.2). Cardiovascular risk factors 
that were positively associated with XO activity were BMI Z-score (R=0.41, p<0.01), 
waist circumference (R=0.41, p<0.01), and oxidized LDL (R=0.57, p=0.05). CVD risk 
factors/adipokines that were negatively associated with XO activity were HDL (R=-0.32, 
p=0.04), adiponectin (R=-0.53, p=0.04), and MCP-1 (R=-0.59, p=0.02)(Table 3.3). 
3.4 Discussion: 
 Childhood obesity is associated with cardiovascular disease risk factors such as 
elevated systolic blood pressure, LDL, triglycerides, and insulin, and low HDL levels. In 
addition, obese children have adverse levels of cytokines/adipokines (i.e. elevated leptin, 
CRP, IL-6, and a reduction in adiponectin).120 In this study we examined the association 
of childhood obesity and cardiovascular risk factors on XO activity as a marker of 
oxidative stress. We directly measured XO activity in the plasma by measuring the 
conversion of lumazine to isoxantholumazine instead of measuring plasma uric acid 
levels as an indirect method of quantitating XO activity. Using a direct method to 
measure XO is preferable because there are less conflicting variables as compared to 
using uric acid levels, which can change based on differences in diet and the ability to 
eliminate uric acid via the kidneys. The results show that XO activity was significantly 
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increased in obese children and adolescents (3.8 fold increase in XO activity) and that 
this XO activity was significantly associated with CVD risk factors such as BMI Z-score, 
waist circumference, HDL, and oxidized LDL and with the cytokines adiponectin and 
MCP-1.  
 These findings are consistent with previous studies in an obese pediatric 
population whereby in vivo xanthine oxidase activity was increased, as assessed by in 
vivo caffeine phenotyping strategies;32  and high serum uric acid concentrations were 
associated with metabolic syndrome and cardiovascular risks  in similar pediatric 
populations. (Kong and Ford and Pacifico)  We observed that adiponectin was inversely 
associated with XO activity. This finding is similar to previous studies whereby plasma 
uric acid concentration (a surrogate for XO activity) was inversely proportional to 
adiponectin concentrations.121-124 Surprisingly we observed that MCP-1 activity was 
inversely associated with XO activity (Table 3). In vitro studies in whole blood and in 
mononuclear cells demonstrated that MCP-1 is up-regulated in the presence of reactive 
oxidative intermediates that are produced by xanthine oxidase.125 Thus one would 
anticipate that higher xanthine oxidase enzyme activity would lead to more reactive 
oxygen species available to increase MCP-1 expression. A limitation of our study is that 
we were unable to determine in vivo plasma nitric oxide concentrations due to its 
instability. Nitric oxide, unlike XO, is a negative regulator of MCP-1 expression. 
Codoner et al. observed that nitric oxide production is increased in obese children, which 
is contrary to what is observed in obese adults.126 It is plausible that the obese children in 
our population have elevated NO levels which would serve as a better surrogate for 
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MCP-1 expression. There was no correlation of FMD or systolic blood pressure (SBP) 
with XO activity, and this could be due to an elevated NO level seen in the obese 
children. An elevated NO level in the obese group would counteract the increase in ROS 
due to increased XO activity and lead to no net change in dilation of the arteries.  
 In our study, we observed that HDL concentrations were inversely associated with 
XO activity. In vitro studies by Chander and Kapoor, demonstrated that HDL can inhibit 
xanthine oxidase activity by 43% in an in vitro rat liver microsomal system. Thus the 
higher the HDL the lower the xanthine oxidase activity, which would decrease the 
generation of reactive oxygen species associated with this enzyme.127 This inhibitory 
effect of HDL on XO activity could mean that future studies looking at XO activity 
should control for HDL levels. A positive correlation was observed between XO activity 
and oxidized LDL in our study, and this was expected because ROS produced by XO are 
known to be sources of oxidation for LDLs. Oxidized LDL is elevated in severe pediatric 
obesity128 (Nyberg) and is associated with cardiovascular risk factors and insulin 
resistance in children and adolescents.129 (Huang and Nyberg) This positive correlation 
between XO activity and oxidized LDL indicates that XO may play a role in 
atherosclerosis risk in childhood obesity because oxidized LDLs penetrate the 
endothelium and form plaques.130,131 
  In conclusion, plasma XO activity in the obese group was increased by 3.8-fold as 
compared to the normal weight group and was correlated with the CVD risk factors waist 
circumference, HDL, oxidized LDL and with the cytokines adiponectin and MCP-1. 
Results of this study provide evidence of a substantial increase in plasma XO activity in 
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obese children, which could be a factor contributing to increased CVD risk in the context 
of pediatric obesity. The results of this study could provide a basis for targeting and 
inhibiting XO as a measure for preventing CVD in obese children and adolescents. 
Further studies are needed to confirm these findings and to see if inhibiting XO in 
childhood obesity decreases CVD risk. 
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Table 3.1 Baseline Characteristics 
 Weight Classification  
  Lean (n=22) Obese 
(n=20) 
p-value 
Gender (% females) 36 35 0.93 
Age (years) 12 ± 3 12 ± 3 0.6 
Height (cm) 155 ± 16 155 ± 15 0.92 
Weight (kg) 48 ± 16 85 ± 32 <0.001 
Body mass index (kg/m^2) 19 ± 3 33 ± 8 <0.001 
Body mass index Z-score 0.28 ± 0.7 2.4 ± 0.4 <0.001 
Waist circumference (cm) 69 ± 10 108 ± 19 <0.001 
Systolic blood pressure (mm 
Hg) 
104 ± 10 116 ± 12 <0.001 
Diastolic blood pressure (mm 
Hg) 
57 ± 10 61 ± 10 0.07 
Heart rate (beats/min) 74 ± 9 76 ± 11 0.67 
Total cholesterol (mg/dl) 150 ± 27 168 ± 25 0.03 
High-density lipoproteins 
(mg/dl) 
53 ± 11 41 ± 9 <0.001 
Low-density lipoproteins 
(mg/dl) 
85 ± 21 104 ± 20 0.004 
Triglycerides (mg/dl) 62 ± 21 113 ± 57 <0.001 
Glucose (mg/dl) 86 ± 7 85 ± 6 0.24 
Insulin (mU/l) 6 ± 5 13 ± 8 0.002 
Homeostasis model of 
assessment - insulin resistance 
1.4 ± 1.1 2.8 ± 1.8 0.004 
Baseline Brachial Diameter 
(mm) 
3.6 ± 0.8 3.2 ± 0.3 0.24 
Flow-mediated dilation (%) 10.5±5 9.2±2.6 0.587 
 
Data are presented as mean ± standard deviation 
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Table 3.2 Baseline Cytokine and Oxidative Stress Marker Levels 
 Weight Classification  
  Lean (n=7) Obese (n=9) p-value 
Leptin (ng/mL) 6.5 ± 5 53.3 ± 25 <0.01 
Monocyte chemotactic protein-1 
(pg/mL) 289 ± 86 80 ± 42 <0.01 
Serpin E1 (ng/mL) 103 ± 22 16 ± 20 <0.01 
Adiponectin (µg/mL) 16.5 ± 5 11.2 ± 3 0.05 
C-reactive protein (mg/L) 0.4 ± 0.55 4.89 ± 6.12 0.06 
Oxidized low density lipoproteins* 
(U/L) 76 ± 19 97 ± 30 0.18 
Resistin (ng/mL) 8.0 ± 4 6.8 ± 3 0.51 
Factor D (ng/mL) 2.4 ± 0.5 2.3 ± 0.4 0.94 
*lean(n=5) and for obese(n=7)   
Data are presented as mean ± standard deviation 
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Figure 3.1 Plasma xanthine oxidase (XO) activity in normal weight and obese 
children. 
 Isoxantholumazine production from normal weight (n=22) and obese (n=20) plasma 
samples standardized to purified XO standards of known activity. One Unit of XO 
activity is defined as the production of one micromole of uric acid per minute at 25°C. 
Data are means ± SEM. *, p < 0.001 compared to the normal weight group. 
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Table 3.3 Correlations Between Xanthine Oxidase Activity and Oxidative Stress 
Makers and Cytokines 
Cardiovascular disease risk factor 
or cytokine R 
p-
value 
Body mass index (n=42) 0.26 0.10 
Body mass index Z-score (n=42) 0.41 <0.01 
Waist circumference (n=42) 0.41 <0.01 
Systolic blood pressure (n=42) 0.13 0.41 
Diastolic blood pressure (n=42) 0.02 0.88 
Heart rate (n=17) 0.45 0.07 
Total cholesterol (n=41) 0.04 0.82 
High-density lipoproteins (n=41) -0.32 0.04 
Low-density lipoproteins (n=41) 0.08 0.60 
Triglycerides (n=41) 0.29 0.07 
Glucose (n=41) -0.18 0.27 
Insulin (n=39) -0.04 0.78 
Homeostatis model assessment - 
insulin resistance (n=39) 0.06 0.71 
Baseline Brachial Diameter (n=17) -0.18 0.49 
Flow-mediated dilation (n=16) -0.14 0.61 
Oxidized low-density lipoproteins 
(n=12) 0.57 0.05 
C-reactive protein (n=16) 0.07 0.78 
Adiponectin (n=16) -0.53 0.04 
Factor D (n=16) 0.27 0.31 
Leptin (n=16) 0.29 0.27 
Monocyte chemotactic protein-1 
(n=16) -0.59 0.02 
Serpin E1 (n=16) -0.47 0.06 
Resistin (n=16) -0.31 0.25 
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Chapter IV 
Changes in Xanthine Oxidase Activity and Uric Acid Clearance with Modest and 
Massive Weight Loss in Adolescents with Severe Obesity 
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4.1 Introduction: 
Obesity rates in the United States among children and adolescents ages 2-19 years 
old have risen nearly 3-fold since 1980; to a rate of nearly 17% in 2010.132 Childhood 
obesity is known to increase xanthine oxidase (XO) activity and blood pressure, which 
can modulate the cardiovascular risk in these children.41,96,133 Subsequently, elevated XO 
activity leads to increased production of uric acid, which has been shown to modulate 
blood pressure in a two-phase mechanism. 43 The first phase of blood pressure 
modulation is uric acid dependent, whereby uric acid induces the renin-angiotensin 
system (RAS), which leads to acute vasoconstriction and ultimately atherosclerosis. This 
second phase results in chronic hypertension and is uric acid independent and sodium 
dependent. Therefore, studying the effects of uric acid and xanthine oxidase before the 
uric acid independent second phase of hyperuricemic hypertension is crucial to 
determining whether treatment of hyperuricemia is beneficial to treating obesity-
mediated hypertension. 
Elevated XO activity and uric acid levels are known to be correlated with obesity, 
but it is not known whether obesity actually causes increases in XO and uric acid. 
Studying the effect of weight loss on XO activity, uric acid, and blood pressure will give 
us greater insight into the mechanism of how obesity increases cardiovascular risk. 
Additionally, studying these effects in a pediatric population allows for the examination 
of the effect of weight loss on uric acid-mediated changes in blood pressure before 
chronic hypertension has developed. Weight loss can be achieved in a variety of ways; 
including diet modification, pharmacological intervention, or bariatric surgery. Diet 
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intervention via meal replacement therapy (MRT) has been shown to be effective at 
moderately reducing weight in both obese adolescents and adults in a short period of time 
leading to reductions in weight varying from 5-10% after 2-4 months.76,77 Bariatric 
surgery, such as Roux-En-Y gastric bypass (RYGB) surgery has been shown to be safe 
and effective, with 2-3 year BMI reductions ranging from 25-87% in adolescents with 
severe obesity.134 Owing to the large difference in the amount of weight lost between 
MRT and RYGB, evaluating these treatments together represents a unique opportunity to 
determine if a greater degree of weight loss would have a larger effect size on uric acid-
mediated changes in blood pressure. Weight loss has also been shown to reduce the 
elevated cytokine levels and inflammation seen in obese adolescents.135 Cytokines, 
including interleukin-6 and tumor necrosis factor-alpha, have been shown to regulate XO 
expression. 65 Therefore, changes in the levels of cytokines after weight loss may lead to 
changes in XO activity and blood pressure, which makes these cytokines a factor to 
measure to account for any changes in XO activity that may occur after weight loss.  
The primary objective of this study was to determine if modest and/or massive 
weight loss in youth with severe obesity would reduce blood pressure via changes in 
xanthine oxidase activity and plasma uric acid levels. In addition to its production, uric 
acid’s elimination via the kidneys is also a key contributor to changes in plasma uric acid 
levels; therefore, we also measured uric acid clearance. Creatinine clearance was also 
measured to estimate kidney function and glomerular filtration rate (GFR) before and 
after weight loss after MRT to account for any changes in uric acid clearance.  
4.2 Methods: 
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This was an ancillary study within the context of two larger clinical trials in which 
16 adolescents (mean age = 15 ± 2 years) received meal replacement therapy over a 
period of four weeks and 11 adolescents (mean age = 17 ± 2 years) received RYGB. 
Subjects that received MRT were recruited from the Pediatric Weight Management 
Clinic at the University of Minnesota Masonic Children’s Hospital. Subjects that received 
RYGB were recruited from Cincinnati Children’s Hospital Medical Center. Outcomes 
measured at baseline and four weeks after MRT or one year after RYGB included weight 
loss, blood pressure, plasma xanthine oxidase activity, plasma uric acid (MRT only), uric 
acid clearance (MRT only), and creatinine clearance (MRT only). Meal replacement 
therapy consisted of 2 frozen entrees (Weight Watchers, Smart Ones®), 3 Slim-Fast® 
shakes per day, and subjects were allowed to have 2 servings of fruit and 3 servings of 
vegetables per day (other than peas, corn or potatoes) that they provide themselves 
(equating to approximately 1370 kcals per day). 
Parental consent and child assent were obtained from participants in both studies 
and the respective protocols were approved by each sites’ Institutional Review Board.  
Height and weight were obtained using a standard stadiometer and electronic scale, 
respectively, with participants wearing light clothes and no shoes. BMI was calculated as 
weight in kilograms divided by height in meters squared. Waist circumference was 
measured midway between the base of the ribs and the superior iliac crest, to the nearest 
0.5 cm, taken in duplicate and the mean values were used in the analyses. Seated blood 
pressure was obtained after 5 min of quiet rest, on the right arm using an automatic 
sphygmomanometer. Three consecutive blood pressure measurements were taken with a 
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3 minute rest between. Blood pressure was then averaged. Blood samples were collected 
after a minimum 8-hour fast. In the subjects that received MRT, lipids, glucose, and 
insulin assays were conducted with standard procedures at the Fairview Diagnostic 
Laboratories, Fairview-University Medical Center (Minneapolis, MN), Centers for 
Disease Control and Prevention–certified laboratory. Cytokine and oxidative stress 
markers were measured using a Luminex multiplex bead array assay. Measurement of 
oxidative stress and inflammation blood markers in plasma included tumor necrosis 
factor-alpha (TNF-α) and interleukin-6 (IL-6). Plasma was stored frozen at −70 °C until 
assayed at the University of Minnesota Cytokine Reference Laboratory (Clinical 
Laboratory Improvement Amendments licensed) using enzyme-linked immunosorbent 
assay.   
Plasma XO activity was determined by measuring the XO-specific conversion of 
lumazine to isoxantholumazine. Briefly, reaction mixtures contained 100µL plasma and 
100 µL of 80µM lumazine in 50mM potassium phosphate buffer (pH=7.4) and were 
incubated at 37°C for three hours followed by addition of 400µL methanol (with 
umbelliferone as internal standard) to stop the reaction. After centrifugation and 
filtration, the supernatants were saved for HPLC analysis of isoxantholumazine. 100 µL 
of the supernatant was injected onto a 250mm YMC-Pack Phenyl column and 
fluorescence was measured on a Waters 474 Scanning Fluorescence Detector set at 
Excitation wavelength=340nm and Emission wavelength=400nm. 
Statistical Analyses: 
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Paired t-tests were used to compare the changes before and after intervention for 
variables of interest including plasma XO activity. Linear regression analysis was used to 
determine the associations between changes in uric acid vs. changes in blood pressure 
and uric acid clearance vs. creatinine clearance. Data are presented as mean ± standard 
error unless stated otherwise. Statistical significance was set at a p-value ≤ 0.05. 
4.3 Results:  
Meal Replacement: Baseline and post-intervention characteristics are shown for MRT in 
Table 4.1A. After the meal replacement intervention, participants had a decrease in body 
weight (3.7% decrease, 109±16 vs. 105±14 kg, p<0.0001) and BMI (3.4% decrease, 
38.7±4 vs. 37.4±3 kg, p<0.0001), total cholesterol (169±34 and 155±33 mg/dL, 
p=0.0066), HDL cholesterol (43±12 vs. 39±11 mg/dL, p=0.0009), and LDL cholesterol 
(103±31 vs. 94±28 mg/dL, p=0.023). Systolic blood pressure (SBP) was reduced but did 
not achieve statistical significance (122±10 vs. 119±10 mm Hg, p=0.34); whereas 
diastolic blood pressure (DBP) was unchanged (69±8 vs. 69±10, p=0.86). As shown in 
Figure 4.1 plasma XO activity was significantly reduced by 9.8% after four weeks of 
MRT (0.045±0.007 vs. 0.040±0.007 pmol/hour, p-value= 0.0159). Creatinine clearance 
was reduced but did not achieve statistical significance (199±17 vs. 160±17 mL/min, p-
value= 0.10, Figure 4.2), uric acid clearance was significantly decreased by 39% (8.9±1.4 
vs. 5.4±0.7 mL/min, p-value= 0.006, Figure 4.3), and plasma uric acid was reduced but 
did not achieve statistical significance (8.5±0.5 vs. 8.1±0.6 mg/dL, p-value= 0.38, Figure 
4.4). Changes in plasma uric acid levels between baseline and after intervention were 
compared to changes in SBP and DBP, but no significant relationships were found 
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(Figure 4.5). Plasma IL-6 and TNF-α levels were measured (Table 4.1A) at baseline and 
after MRT. IL-6 decreased by 19% (2.2±1.2 vs. 1.8±0.7 pg/mL, p=0.03) and tumor 
necrosis factor-alpha was unchanged (2.6±0.8 vs. 2.6±0.6 pg/mL, p-value= 0.69). 
Bariatric Surgery: Baseline and post-intervention characteristics are shown for RYGB 
in Table 1B. BMI decreased by 37% (58.2±2.3 vs. 36.5±2.1 kg/m2, p-value= <0.0001), 
systolic blood pressure decreased by 10% (124±2.7 vs. 111±2.8 mm Hg, p-value= 
0.0005), and diastolic blood pressure decreased by 13% (76±3.0 vs. 66±1.7 mm Hg, p-
value= 0.029). As shown in Figure 4.1, plasma XO activity was unchanged after bariatric 
surgery (0.035±0.002 vs. 0.033±0.002 pmol/hour, p-value= 0.12). Plasma IL-6 and TNF-
α levels were measured (Table 4.1B) at baseline and after RYGB. Interleukin-6 decreased 
by 69% (1.1±0.3 vs. 0.34±0.3 pg/mL, p-value= 0.0316) and tumor necrosis factor-alpha 
was unchanged (1.0±0.2 vs. 0.89±0.3 pg/mL, p-value= 0.52). 
4.4 Discussion:  
 It has been demonstrated that childhood obesity elevates xanthine oxidase 
activity, and that XO activity is correlated with pediatric cardiovascular risk factors.96,133 
In obese children, elevated XO activity often results in the subsequent increase in plasma 
uric acid concentrations which may modify cardiovascular disease risk by modifying 
blood pressure through activation of the renin angiotensin system. 43,96,133,136  Because 
obesity causes an elevation in XO activity and is a risk factor for cardiovascular disease 
in children, we hypothesized that weight loss would reverse the increase in XO activity 
that is seen in obesity, ultimately lowering both plasma uric acid concentrations and 
blood pressure.  In this study we report that modest weight loss with MRT results in 
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reduction of XO activity, while massive weight loss with RYGB did not significantly 
alter XO activity. 
 It was not surprising to observe that weight loss via MRT resulted in the lowering 
of xanthine oxidase activity. There are multiple factors that regulate XO activity such as 
cytokines65 and lipopolysaccharide (LPS)66,67. The cytokine IL-6 plays an important 
regulatory role in the expression of xanthine oxidase, due the presence of IL-6 binding 
sites in the promoter region of the xanthine oxidoreductase gene.62 Therefore the 19% 
decrease in plasma IL-6 concentrations may be partially responsible for the lowering in 
overall XO activity due to a reduction in XO expression, but the correlation between the 
changes in IL-6 were not significantly associated with the changes in XO activity (data 
not shown). Contrary to other studies, we observed weight loss mediated changes only in 
IL-6 and not in TNF- α concentrations (Table 4.1A). Jung et al. and Ziccardi et al. both 
reported significant decreases in multiple inflammatory cytokines including IL-6 and 
TNF-α after weight loss of at least 10% of baseline weight, but our MRT population 
averaged a weight loss of  only 3.7%.137,138 Therefore, TNF-α may not have been as 
sensitive to weight loss as IL-6 and/or our MRT subjects may not have lost enough 
weight to observe TNF-α changes. Another possible factor that may regulate plasma XO 
activity is plasma LPS concentration generated by bacteria.  Kurosaki et al. reported that 
mice exposed to LPS induced XO expression in various organs and tissues, therefore 
changes in the gut microbiota and LPS exposure from this source may contribute to 
changes in XO activity in our study.67  For example, a high fat diet or high consumption 
of dietary fats, which are common in subjects with extreme obesity, may also increase 
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LPS levels by altering the gut microbiota to express more gram negative bacteria.71,72 
MRT may be partially responsible for changes in XO activity by altering the gut 
microbiota to decrease LPS production because the MRT used in our study has less fat 
than an average diet (19% fat in MRT vs. 33% in an average U.S. diet), and MRT has 
been shown in previous studies to lower LPS levels in obese adolescents.139   
Modest weight loss via diet replacement therapy lowered plasma XO activity by 
9.8%, but XO activity was surprisingly unchanged after a substantial amount of weight 
was lost via bariatric surgery. The primary explanation for the dissimilar results on the 
impact on weight loss on xanthine oxidase activity may be due to the surgery induced 
changes in the gut microbiota. While MRT may lead to decreases in LPS, RYGB surgery 
has been shown to increase LPS expression by altering the gut microbiota to a population 
which has more LPS-expressing gram negative bacteria.82 This change in gut microbiota 
is likely due to changes in the amount of free bile acids in the intestinal tract. In the 
normal enterohepatic circulation, conjugated bile acids are secreted into the duodenum to 
mix with fatty acids to aid in their digestion, and any free bile acids are then reabsorbed 
in the ileum. After RYGB serum bile acids increase and this is attributed to the fact that 
bile acids and food have less time to mix and more free bile acids are reabsorbed at the 
ileum.81 More free bile acids will select for bile-tolerant bacteria, such as the gram 
negative proteobacteria, which will lead to increased LPS and XO expression. 82 
Therefore, opposing changes in the gut microbiota between the different weight loss 
methods led to differing effects on xanthine oxidase activity. 
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Uric acid has been shown to be important in regulating blood pressure in children 
with hypertension.136  Plasma uric acid levels depend on its production rate via XO and 
its elimination rate primarily via the kidneys.  We observed that XO activity is reduced 
after weight loss (Figure 4.1). However both plasma uric acid and blood pressure were 
unchanged after MRT intervention (Table 4.1A and Figure 4.4). Therefore, we measured 
creatinine clearance and uric acid clearance before and after weight loss to determine if 
weight loss is affecting plasma uric acid levels via changes in kidney function and the 
elimination of uric acid. Uric acid clearance decreased by 39% with weight loss (Figure 
4.3) and it is mirrored by a reduction in creatinine clearance (Figure 4.2). These decreases 
are likely due to reversion of renal hemodynamic overload with glomerular 
hyperfiltration that is seen with obesity.  For example, it has been previously shown that 
weight loss decreases creatinine clearance in obese adults with metabolic syndrome and 
diabetic nephropathy.140,141 The decrease in uric acid clearance that we observe may be 
due to changes in the filtration rate of uric acid, as creatinine clearance (a common 
surrogate for glomerular filtration rate) is related uric acid clearance (r2 = 0.47, Figure 
4.6); or there may be changes in the reabsorption of uric acid, as the change in uric acid 
clearance is greater than the change in creatinine clearance uric acid (39% decrease vs. 
19% decrease) and uric acid is known to be highly reabsorbed by multiple transporters. 
The discrepancy between the decreases in creatinine clearance and uric acid clearance 
indicate that there is an increase in uric acid reabsorption. If uric acid reabsorption was 
saturated before weight loss, decreasing the filtration rate of uric acid would effectively 
increase the percentage of uric acid that is reabsorbed, and this would compound the 
 83 
 
change in GFR to generate a greater change in uric acid clearance. Therefore, future 
studies should continue to measure uric acid clearance as changes in creatinine clearance 
underestimate the changes in uric acid clearance due to the reabsorption of uric acid. 
Overall, the opposing changes in uric acid production and elimination resulted in 
no net change in plasma uric acid levels, which would explain why there was no change 
in blood pressure after weight loss. Having no net change in plasma uric acid was 
surprising, as our subjects had very high levels of plasma uric acid (mean of 8.5mg/dL at 
baseline) that would be considered as hyperuricemic even in adults (cutoff values of 
hyperuricemia are 5.8mg/dL in women and 6.8mg/dL in men). Hyperuricemia persisted 
in our subjects even after weight loss, which would indicate that the mean decrease of 
BMI by 1.3 was not sufficient to lower cardiovascular risk by affecting either plasma uric 
acid or blood pressure. This high level of uric acid in our subjects may lead to damage to 
the kidneys via RAS activation and lead to sodium dependent hypertension in the future. 
Therefore, the decrease in XO activity due to weight loss was not sufficient to lower 
plasma uric acid, and administration of ace inhibitors or angiotensin receptor blockers to 
counter-act the effects of uric acid mediated RAS activation should be considered to 
lower the cardiovascular risk of uric acid. Early intervention and treatment of 
hyperuricemia before sodium dependent hypertension is established is crucial, as 
treatment of hyperuricemia in adults has been shown to not be as effective of a measure 
to treat hypertension compared to children (3.3 mm Hg decrease in SBP vs. 6.9 mm Hg 
decrease in SBP).136,142 
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  A limitation of this study was the fact that blood pressure did not significantly 
change in the MRT cohort due to several factors. The amount of weight lost was 
relatively low (3.7%) and it is unknown if further weight loss via this method would lead 
to significant changes in plasma uric acid and blood pressure. Blood pressure in our MRT 
cohort were also slightly elevated, but most were not considered as hypertensive (≥95th 
percentile) and this may have been a contributing factor to why we did not see a 
significant change in blood pressure with MRT. In our RYGB cohort, decreases in blood 
pressure were observed after one year, but plasma uric acid levels and uric acid clearance 
were not measured in this cohort. Therefore, uric acid’s effect on blood pressure in this 
cohort could not be ascertained. Including uric acid levels from plasma and urine in 
future studies would enable us to determine how RYGB alters uric acid levels and its 
effects on blood pressure after weight loss. Future studies should include an evaluation of 
LPS levels with XO activity in future weight loss studies to determine if decreased LPS 
could be responsible for changes in XO activity due to MRT or RYGP.  
In conclusion, the relationship between uric acid and blood pressure in obesity 
remains inconclusive, as changes in XO activity and uric acid levels did not correlate 
with changes in blood pressure after weight loss. However, weight loss via MRT in an 
obese pediatric population did lead to decreases in uric acid production by lowering 
xanthine oxidase activity and decreases in uric acid clearance via a decrease in GFR and 
a likely increase in reabsorption. The opposing changes of lower production and 
elimination may explain why we did not find significant changes in plasma uric acid 
levels or blood pressure. In our RYGB cohort, XO activity did not decrease and blood 
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pressure was significantly reduced, but without uric acid levels and clearance, the 
relationship between XO, uric acid, and blood pressure could not be determined. 
Differences in the changes to XO activity between the methods of weight loss may be 
due to opposing changes in the gut microbiota between the different weight loss methods, 
but the ultimate role this plays in uric acid levels and its effect on blood pressure has yet 
to be determined. 
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Table 4.1A Baseline and Post-MRT Characteristics 
  Baseline (n=16) 
After 
MRT 
(n=16) 
p-value 
Gender (% females) 69 N/A - 
Age (years) 14.6 ± 2 14.8 ± 2 - 
Height (cm) 168 ± 8 167 ± 8 - 
Weight (kg) 109.2 ± 16 105.2 ± 14 <0.0001* 
Body mass index (kg/m^2) 38.7 ± 4 37.4 ± 3 <0.0001* 
Waist circumference (cm) 110 ± 12 108 ± 12 0.36 
Systolic blood pressure (mm Hg) 122 ± 10 119 ± 10 0.34 
Systolic blood pressure percentile 
(%) 73 ± 18 70 ± 23 0.53 
Diastolic blood pressure (mm Hg) 69 ± 8 69 ± 10 0.86 
Diastolic blood pressure percentile 
(%) 59 ± 22 64 ± 25 0.39 
Heart rate (beats/min) 76 ± 7 74 ± 10 0.37 
Total cholesterol (mg/dl) 169 ± 34 155 ± 33 0.0066* 
High-density lipoproteins (mg/dl) 43 ± 12 39 ± 11 0.0009* 
Low-density lipoproteins (mg/dl) 103 ± 31 94 ± 28 0.023* 
Triglycerides (mg/dl) 119 ± 58 114 ± 56 0.68 
Glucose (mg/dl) 84 ± 8 81 ± 7 0.30 
Insulin (mU/l) 24 ± 12 23 ± 9 0.60 
IL-6 (pg/mL) 2.2 ± 1.2 1.8 ± 0.7 0.03* 
TNF-alpha (pg/mL) 2.6 ± 0.8 2.6 ± 0.6 0.69 
Data are presented as mean ± standard deviation 
*p-value<0.05 
 
Table 4.1B Baseline and Post-RYGB Characteristics 
  Baseline (n=11) 
After 
RYGB 
(n=11) 
p-value 
Gender (% females) 73 N/A - 
Age (years) 16.7 ± 0.5 17.7 ± 0.5 - 
Body mass index (kg/m^2) 58.2 ± 2 36.5 ± 2 <0.0001 
Systolic blood pressure (mm Hg) 124 ± 2.7 111 ± 2.8 0.0005 
Diastolic blood pressure (mm Hg) 76 ± 3.0 66 ± 1.7 0.0294 
Interleukin-6 (pg/mL) 1.1 ± 0.3 0.34 ± 0.3 0.0316 
Tumor necrosis factor-alpha (pg/mL) 1.0 ± 0.2 0.89 ± 0.3 0.52 
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Figure 4.1 Plasma xanthine oxidase activity before and after intervention. 
 
Plasma XO activity was determined by isoxantholumazine production from plasma. A 
paired t-test was used to determine the differences between subjects at baseline and 
subjects after intervention for changes in XO activity. n=16 for MRT and n=11 for 
RYGB. Data are means ± SEM. *p-value= 0.0159 compared to the baseline. 
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Figure 4.2 Creatinine Clearance at Baseline and After MRT Intervention 
 
A paired t-test was used to determine the differences between subjects at baseline and 
subjects after intervention for changes in creatinine clearance. Creatinine clearance was 
calculated using serum creatinine levels and urine creatinine levels (1-6 hour collection 
interval) by using the following equation:  
(Urine creatinine/plasma creatinine) x (urine volume/collection interval) 
n=14 
p-value= 0.10 
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Figure 4.3 Uric Acid Clearance at Baseline and After MRT Intervention 
 
A paired t-test was used to determine the differences between subjects at baseline and 
subjects after intervention for changes in uric acid clearance. Uric Acid clearance was 
calculated using serum creatinine levels and urine creatinine levels (1-6 hour collection 
interval) by using the following equation:  
(Urine uric acid/plasma uric acid) x (urine volume/collection interval) 
n=14 
*p-value= 0.006 
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Figure 4.4 Plasma Uric Acid Levels at Baseline and After MRT Intervention 
 
A paired t-test was used to determine the differences between subjects at baseline and 
subjects after intervention for changes in uric acid.  
n=16 
p-value= 0.38 
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Figure 4.5 Linear Regression of the Changes in Uric Acid vs. the Change in Blood 
Pressure in MRT Subjects 
 
Linear regression analysis was used to determine the association between the change in 
uric acid clearance vs. systolic blood pressure (r2= 0.12) and vs. diastolic blood pressure 
(r2= 0.13). 
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Figure 4.6 Creatinine vs. Uric Acid Clearance in MRT Subjects 
 
Linear regression analysis was used to determine the association between uric acid 
clearance and creatinine clearance. r2= 0.47 
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Chapter V 
Development and Optimization of Screening Assays for UDP-
Glucuronosyltransferase Inhibition and Time-Dependent Inhibition of Cytochrome 
P450s in Hepatocytes 
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5.1 Introduction 
 Cytochrome P450s (CYPs) and glucuronosyltransferases (UGTs) are major 
families of oxidative and conjugative drug metabolizing enzymes. In vitro phenotyping 
with human liver microsomes (microsomes contain the endoplasmic reticulum of cells 
which that contain membrane-associated drug metabolizing enzymes) in conjunction with 
specific inhibitors of drug metabolizing enzymes is a common strategy to identify and 
determine the enzymes responsible for a drug’s metabolism. For CYPs, there are many 
selective inhibitors available to probe specific CYP isozymes (table 5.1). However, with 
UGTs, only a few selective inhibitors have been identified; which makes the use of 
microsomes to identify the UGTs responsible for a drug’s metabolism very difficult. 
Therefore, the primary objective of this project was to develop screening assays to 
identify specific inhibitors of UGTs. The first step in this process is to determine 
selective substrates for UGTs, which can then be used to identify inhibitors of UGTs. 
After that, optimization of UGT assays with the addition of alamethacin and albumin will 
be tested. UGTs are oriented towards the luminal side of the endoplasmic reticulum, and 
the membrane of the endoplasmic reticulum needs to be disrupted to increase the amount 
of substrate and uridine 5’-diphospho-glucuronic acid (UDPGA) that reaches the active 
site of UGTs.143 Alamethacin can be used to disrupt the membrane of the endoplasmic 
reticulum because it is an antibiotic peptide that inserts into the membrane and forms 
pores/channels.143 The effect of albumin addition to incubations will be tested because it 
has been found to alter the kinetics of some UGT substrates by sequestering fatty acids 
that can inhibit UGT activity.144 
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 In addition to developing and optimizing screening assays for UGTs, inhibition of 
CYPs, specifically time-dependent inhibition (TDI) of CYPs, was also studied. TDI of 
CYPs occurs when a substrate is metabolized to a reactive intermediate that binds to and 
inactivates the enzyme that produced it. Most studies of TDI in CYPs have been done in 
microsomes, but we wanted to determine if there were differences in TDI in hepatocyte 
cell culture compared to human liver microsomes (HLMs). Cell culture, which uses liver 
cells from donors, is more similar to in vivo conditions than the more artificial HLM 
system, which may make it a more translatable system to study TDI. For example, cell 
culture is more similar to in vivo conditions due to the fact that it is a more complete 
system, in which all transporters are present, while they are not present in HLMs. 
Therefore, we studied TDI in cell culture to determine if established time-dependent 
inhibitors in HLMs had similar inhibition potential in cell culture. 
Table 5.1: Substrates and Inhibitors of CYPs in humans: 
Enzyme Substrate Inhibitor 
1A2 Theophylline, Caffeine Fluvoxamine, Furafylline 
2B6 Efavirenz, Bupropion Ticlopidine, Thiotepa 
2C8 Repaglinide, Rosiglitazone Gemfibrozil, Montelukast 
2C9 S-Warfarin, Flurbiprofen Fluconazole, Sulfaphenazole 
2C19 Esomeprazole, Lansoprazole Fluvoxamine, Moclobemide 
2D6 Desipramine, Dextromethorphan Paroxetine, Quinidine, Fluoxetine 
2E1 Chlorzoxazone Disulfiram 
3A4/3A5 Midazolam, Triazolam Atazanavir, Itraconazole, Azamulin 
 
5.2 Methods 
General Incubation Conditions 
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100mM Tris buffer pH 7.4 at 37˚C, 1mM MgCl, 5mM saccharolactone, 0.1mg/ml protein 
concentration for recombinant UGTs (rUGTs), and 0.2mg/mL protein concentration for 
HLMs. 
Substrate selectivity 
 Five substrates were tested for substrate selectivity with 12 human recombinant 
UGTs. The five substrates tested were estradiol, trifluoperazine (TFP), 1-naphthol, 
propofol, and zidovudine (AZT); these substrates were selected based on a literature 
search for selective probe substrates for UGTs.143,145-149 The 12 recombinant UGTs tested 
were UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17. 
Substrate concentrations, incubation times, microsome concentrations, and alamethacin 
concentrations used are listed in Table 5.2. Total activity was calculated by adding up the 
production of glucuronide by each UGT isoform, and percentage of total activity was 
calculated by dividing the production of glucuronide by a single UGT isoform by the 
total activity. 
Table 5.2: Substrates and Incubation Conditions used to Determine Substrate 
Selectivity 
Substrates 
Substrate 
concentration 
(µM) 
Incubation 
time (min) 
Microsome protein 
concentration 
(mg/mL) 
Alamethacin 
(µg/mL) 
Estradiol 6 20 0.1 25 
Trifluoperazine 100 10 0.1 25 
1-Naphthol 27 20 0.1 25 
Propofol 30 20 0.1 25 
Zidovudine 600 10 0.1 25 
 
Effect of Alamethacin Addition and Pre-incubation Times 
Incubations were done with or without the addition of 2.5 mg/mL alamethacin in 
50% methanol (final concentration of 25 µg/mL). Zero, ten, and twenty minutes pre-
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incubation times on ice were tested with the addition of alamethacin. Substrate 
concentrations used varied between substrates, but ranges included concentrations in the 
linear range as well as concentrations that were at saturation. Incubation times were the 
same as those listed in Table X. for each listed substrate. Microsomal protein 
concentrations were 0.2mg/mL for all incubations. 
Effect of Albumin Addition 
Incubations were done at 37°C for 20 minutes with or without the addition of 
bovine or human serum albumin (2% w/v).  Substrate concentrations used varied between 
substrates, but ranges included concentrations in the linear range as well as 
concentrations that were at saturation (Supplemental table X.). Microsome concentrations 
and alamethacin concentrations were the same as those listed in Table X. for each listed 
substrate. 
Screening for UGT Inhibition by Antibodies 
 Incubation conditions were the same as those listed in Table 5.1. Three antibodies 
were tested for UGT1A1 inhibition along with 2 chemical inhibitors as positive controls. 
2 ratios (mg antibody: mg rUGT) or concentrations of inhibitors were used where 
possible. A ratio of 2:1 was used for antibody 1, 1:1 and 3:1 for antibody 2, and 1.25:1 
and 2.5:1 for antibody 3. Concentrations of 50µM and 200µM were used for 4-
nitrophenol and 5µM and 20µM silibinin were used as chemical inhibitors. Incubations 
were done at 37°C and stopped by addition of 2x volume acetonitrile containing internal 
standard. 
TDI of CYPs in Hepatocytes 
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 Four known time-dependent inhibitors of CYPs in HLMs were tested in 
hepatocyte suspensions and compared to literature values of KI and kinact in both HLMs 
and hepatocytes. Paroxetine was used as a time-dependent inhibitor of CYP2D6 and 
dextromethorphan was used as a probe substrate. Tienilic acid was used as an inhibitor of 
CYP2C9 and tolbutamide was used as a probe substrate. Mifepristone and 
troleandomycin were used as inhibitors of CYP3A4 and testosterone was used as a probe 
substrate. Incubations were done in duplicate for paroxetine and tienilic acid and as a 
single replicate for mifepristone and troleandomycin at saturating concentrations of probe 
substrates with 50,000 cells per incubation. Inhibitor pre-incubation times used for 
paroxetine and tienilic acid were 0, 15, 30, 60, and 120 minutes; and times used for 
mifepristone and troleandomycin were 0, 10, 20, 30, 45, 60, 90, and 120 minutes. Kobs 
was determined by calculating the slopes of linear regressions of the data, plotted with 
inhibitor pre-incubation times on the x-axis versus the natural log of the % remaining 
activity on the y-axis. Kobs was then plotted (y-axis) versus inhibitor concentration (x-
axis) to determine KI and kinact which were used to determine inhibition potency (kinact/ 
KI). 
5.3 Results 
Substrate selectivity 
 As shown in Figure 5.1 the majority of the glucuronidation of estradiol was done 
by UGT1A1, 72% of total activity, while UGTs 1A3, 1A8, and 1A10 also contributed 
slightly to the glucuronidation of estradiol with 7.5%, 6.8%, and 11.4% of total activity 
respectively. If we look at only the UGTs that are expressed in the liver (Figure 5.2), then 
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only UGT1A1 and 1A3 have noticeable amounts of glucuronidation making up 88% and 
9% of the total liver activity respectively. For 1-naphthol the majority of the 
glucuronidation was done by UGT1A6, 74% of total activity, while UGTs 1A7, 1A8, and 
1A9 contributed slightly to the glucuronidation of 1-naphthol with 4%, 6.7%, and 5.4% 
of total activity respectively. For UGTs expressed in the liver, only UGT1A6 and 1A9 
have substantial amounts of glucuronidation, making up 85.5% and 6.3% of the total liver 
activity respectively. The glucuronidation of propofol was mediated by UGTs 1A7 and 
1A9, accounting for 37% and 60.2% of total activity respectively. When we only 
consider UGTs in the liver, UGT1A9 accounts for 99.5% of total liver activity. For AZT 
the only UGT that contributed to its glucuronidation was UGT2B7, accounting for 99% 
of total and liver activity. TFP was only glucuronidated by UGT1A4, accounting for 99% 
of both the total and liver activity. 
Effect of Alamethacin Addition and Pre-incubation Times 
 For all substrates tested, the absence of alamethacin decreased activity, increased 
variability between replicates, and made fitting the data accurately not possible. When 
comparing pre-incubation times with alamethacin in estradiol glucuronidation, having no 
pre-incubation resulted in an intrinsic clearance (CLint) of 65.1 µL/min/mg, a 10 minute 
pre-incubation resulted in a slightly increased CLint of 70.6 µL/min/mg, and a 20 minute 
pre-incubation resulted in a slightly increased CLint of 71.3 µL/min/mg.(Figure 5.3) When 
TFP glucuronidation is fitted to a substrate inhibition model, having no pre-incubation 
resulted in KI of 0.11µM and a CLint of 47.8 µL/min/mg, a 10 minute pre-incubation 
resulted in a KI of 0.52µM and a CLint of 44.0 µL/min/mg, and a 20 minute pre-
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incubation resulted in an increased KI of 72µM and a CLint of 53.9 µL/min/mg. (Figure 
5.4) When comparing pre-incubation times with alamethacin in 1-naphthol 
glucuronidation, having no pre-incubation resulted in an CLint of 577 µL/min/mg, a 10 
minute pre-incubation resulted in a slightly increased CLint of 611 µL/min/mg, and a 20 
minute pre-incubation resulted in a slightly increased CLint of 822 µL/min/mg. (Figure 
5.5) When comparing pre-incubation times with alamethacin in propofol glucuronidation, 
having no pre-incubation resulted in an CLint of 94.3 µL/min/mg, a 10 minute pre-
incubation resulted in a slightly increased CLint of 98.7 µL/min/mg, and a 20 minute pre-
incubation resulted in a slightly decreased CLint of 71.9 µL/min/mg. (Figure 5.6) When 
comparing pre-incubation times with alamethacin in AZT glucuronidation, having no 
pre-incubation resulted in an CLint of 1.00 µL/min/mg, a 10 minute pre-incubation 
resulted in a slightly increased CLint of 1.17 µL/min/mg, and a 20 minute pre-incubation 
resulted in an increased CLint of 1.50 µL/min/mg. (Figure 5.7) 
Effect of Albumin Addition 
 For estradiol glucuronidation adding albumin to the incubations altered the 
kinetics fitting from a substrate activation model to a linear model. (Figure 5.8) The 
addition of either human or bovine serum albumin to the incubations with TFP decreased 
CLint from 44.9 µL/min/mg to 20.4 µL/min/mg and 8.3 µL/min/mg respectively. (Figure 
5.9) 1-Naphtol incubations with human or bovine serum albumin led to decreased CLint 
from 957 µL/min/mg to 841 µL/min/mg and 582 µL/min/mg respectively. (Figure 5.10) 
For propofol incubations the addition of human or bovine serum albumin increased CLint 
from 128 µL/min/mg to 172 µL/min/mg and 192 µL/min/mg respectively. (Figure 5.11) 
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AZT incubations with human or bovine serum albumin led to increased CLint from 1.2 
µL/min/mg to 6.3 µL/min/mg and 18.8 µL/min/mg respectively. (Figure 5.12) 
Screening for UGT Inhibition by Antibodies 
 As shown in Figure 5.13, antibody 1 showed no inhibition capability of UGT1A1 
when compared to control at a 2:1 ratio (97% activity remaining). Antibody 2 showed no 
inhibition capability at a 1:1 ratio (110% activity of control) or at a 3:1 ratio (110% 
activity of control). Antibody 3 did inhibit UGT 1A1 activity at both ratios of 1.25:1 
(52% activity remaining) and 2.5:1 (20% activity remaining). 4-Nitrophenol showed no 
inhibition at 50µM (107% activity remaining) and a little inhibition at 200µM (80% 
activity remaining). Silibinin showed inhibition at both 5µM (48% activity remaining) 
and 20µM (6% activity remaining). 
TDI of CYPs in Hepatocytes 
 Paroxetine had a maximal inhibition of 75%, kinact = 0.009 min-1, KI= 0.33µM, 
and a inhibitory potency = 27 mL/µmol/min. (Figures 5.14-5.15) Tienilic acid had a 
maximal inhibition of 80%, kinact = 0.03 min-1, KI= 0.65µM, and a inhibitory potency = 
46 mL/µmol/min. (Figures 5.16-5.17) Mifepristone had a maximal inhibition of 55%, 
kinact = 0.02 min-1, KI= 5.8µM, and a inhibitory potency = 3.4 mL/µmol/min. (Figures 
5.18-5.19) Troleandomycin had a maximal inhibition of 55%, kinact = 0.04 min-1, KI= 
0.28µM, and a inhibitory potency = 143 mL/µmol/min. (Figures 5.20-5.21) 
5.4 Discussion 
 All five of the UGT substrates tested are specific for one UGT in HLMs even 
though some of these substrates can be metabolized by extrahepatic UGTs. Estradiol is 
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selective for UGT1A1, TFP for UGT1A4, 1-naphthol for UGT1A6, propofol for 
UGT1A9, and AZT for UGT2B7 as had been previously reported for each of these 
substrates. Using these substrates as probes, one can screen for inhibitors of each of the 
five UGTs these substrates are probing. 
 The addition of alamethacin to UGT incubations increases activity, decreases 
variability between samples, and the data can be fitted more accurately. Pre-incubation 
with alamethacin on ice increased the CLint and decreased km in most cases, but vmax 
varied with 2 substrates increasing with pre-incubation time and 3 substrates decreasing 
with pre-incubation time. The longer pre-incubation times likely increase the CLint by 
affecting km, but longer pre-incubation times also decreases turnover/vmax, likely due to 
degradation of the microsomes. Therefore, a ten minute pre-incubation time with 
alamethacin is a good compromise to balance the increase in CLint and decrease in overall 
turnover/ vmax. 
The addition of albumin increased the CLint for substrates glucuronidated by 
UGTs 1A9 and 2B7 as expected, but decreased CLint for substrates glucuronidated for the 
other UGTs. The decreases in apparent km are likely due to increases in protein binding 
of substrate and lowering of the free fraction of substrate available as shown previously 
by Walsky et al.143 Human serum albumin had a slightly smaller effect on propofol and 
AZT glucuronidation than bovine serum albumin and it is also more costly. Therefore, if 
albumin is added to incubations, bovine serum albumin should be used instead of human 
serum albumin. The addition of albumin to incubations has a large effect on substrate 
binding, which adds another step in order to counteract this effect, and its addition does 
 103 
 
not benefit the majority of UGTs. Therefore, the addition of albumin should be reserved 
for UGTs 1A9 and 2B7, but the binding of all substrates and inhibitors should always be 
taken into account when adding in albumin. 
The use of antibodies as selective inhibitors has been a strategy that has been used 
for CYP inhibition, but not for UGTs. More and more UGT antibodies are being 
developed and together with the use of UGT inhibition screening assays, selective UGT 
inhibitor antibodies can be discovered. Using an estradiol assay, we screened for 
UGT1A1 inhibitory antibodies. We discovered that UGT1A1 antibody 3 is indeed an 
inhibitor of estradiol glucuronidation, but much more needs to be done in order to see if it 
is a selective inhibitor for UGT1A1. The next steps to be taken are to test this UGT1A1 
antibody for inhibition of other UGT isoforms to make sure that it does not have any 
cross-reactivity. Future studies can also use the assays for UGT1A4, UGT1A6, UGT1A9, 
and UGT2B7 to test for inhibitors of those isoforms. 
 The inhibition potency of time-dependent inhibitors of CYPs in hepatocytes was 
less than inhibition potencies in HLMs in all of the tested inhibitors. This lower inhibition 
potency may be due to efflux of the substrate by transporters in the hepatocytes that are 
not present in HLMs or that the substrate concentration in the cell at the enzyme active 
site is different than the concentration added to the media. Therefore, testing for TDI in 
HLMs may overestimate the inhibition potency of drugs in vivo, which would make 
testing for TDI in hepatocytes more accurate when translating findings to in vivo settings. 
 In conclusion, with the five substrates, namely estradiol, TFP, naphthol, propofol, 
and AZT as probes we can find inhibitors of each of the five UGTs selective for these 
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substrates. In addition, to optimize the UGT activity assays, the addition of alamethacin 
(25µg/mL) with a 10 minute pre-incubation time was ideal to increase activity and 
decrease variability between samples, and the addition of albumin was not needed as it 
may increase substrate binding and lower the free concentration of substrates which may 
confound data in inhibition studies, except for studies with UGT1A9 and UGT2B7. 
Lastly, the inhibition potency of time-dependent inhibitors is dependent on the assay 
method, with cell culture incubations exhibiting lower inhibition potency. 
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Figure 5.1 
 
n=3, protein content=0.2mg/mL 
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Figure 5.2  
 
n=3, protein content=0.2mg/mL 
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Figure 5.13 
 
UGT protein content = 0.1mg/mL 
n=2 
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Chapter VI 
The Effect of High-fat Diet on Intestinal Uridine Diphosphate  
Glucuronosyltransferase Activity 
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6.1 Introduction: 
High fat diet (HFD) and obesity are known to alter the hepatic activity of oxidative 
and conjugative drug-metabolizing enzymes. Studies have shown that obesity and diet 
mediated changes in cytochrome P450s (CYPs) and uridine diphosphate 
glucuronosyltransferases (UGTs) result in to altered drug clearance.31,150 Alterations in 
the expression and activity of CYPs have been reported in both animal models of obesity 
and in clinical studies in obese humans, while alterations in UGT expression and activity 
have only been studied in animal models of obesity. The animal models of obesity that 
are most prevalent are genetic models, which are caused by single point mutations 
leading to a loss of leptin or loss of leptin receptor activity; which leads animals to 
overeat and become overweight within weeks after birth. The major concern with 
studying obesity in models which lack leptin activity is that obesity in humans is rarely 
caused a loss in leptin activity, and in fact an increase in leptin is characteristic of human 
obesity.84  
Diet induced models of obesity are more similar to human obesity than genetic 
models of obesity, and they lead to clinical symptoms that are also present in human 
obesity such as insulin resistance, elevated cholesterol, elevated triglycerides, and 
elevated plasma leptin levels when compared with controls on a standard diet. Diet-
induced models of obesity are achieved by allowing normal-weight animals free access to 
high fat diets (HFDs), which contain similar amounts of fat content contained in modern 
western diets. Furthermore, animals may be selected for their resistance to developing 
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obesity or for their lack thereof by testing animals with a high-fat diet (HFD). 
Differentiation with a HFD to select for obesity resistance or proneness through multiple 
generations helps to mimic obesity that is seen in humans, in which polygenic obesity is 
most prevalent. The obesity resistant animal models do not gain significant amounts of 
weight whether they are fed a LFD or a HFD; while the obesity prone animal models will 
gain significant amounts of weight when fed a HFD. These animal models can be used to 
determine if there both are diet-mediated and weight/obesity-mediated changes in drug 
metabolism. 
Alterations in drug metabolism have been extensively studied in hepatic tissue, but 
extrahepatic metabolism, specifically as it relates to the small intestine, also plays a major 
role in drug metabolism.  There is limited knowledge on the effect of HFD or obesity on 
small intestinal drug metabolism. HFD and obesity have been shown to mediate many 
biological changes in the intestine including increased inflammation due to modified 
expression levels of cytokines and adipokines.151 We hypothesize that modified levels of 
cytokines could lead to altered expression and activity of UGTs. Therefore, the aim of 
this study was to characterize the differences in activity of various intestinal isoforms of 
UGTs in a diet-induced model of obesity in obesity resistant rats and obesity prone rats.  
6.2 Methods: 
 Sprague-Dawley rats were separated based on susceptibility to diet-induced obesity, 
with rats that were highly susceptible to weight gain being grouped into the obesity prone 
(OP) group and the rats with low susceptibility being grouped into the obesity resistant 
(OR) group. OP and OR rats were then bred within each group over multiple (>30) 
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generations before being used in the current study. 
 Whole intestinal tissue samples were isolated from 14 week-old rats (both OR and 
OP) fed either a standard low fat diet (LFD) or HFD. Pooled intestinal microsomes from 
these tissue samples (n=3 animals from each group) were isolated using previously 
described methods.152 4-methylumbelliferone (4-MU) was used to probe the general UGT 
activity while, estradiol 3-O-glucuronidation was used to probe for UGT1a1 activity, and 
acetaminophen (APAP) was used to probe UGT1a6 and UGT1a7. Incubations were 
carried out as listed in Table 1 at 37°C and terminated with methanol containing listed 
internal standards. Intrinsic clearance (CLint) of substrates was calculated by dividing its 
maximal velocity (Vmax) by its binding affinity (km). 
Table 6.1 Incubation conditions 
Enzyme Substrate 
Incubation 
time (min) 
Metabolite 
Protein conc 
(mg/ml) 
Internal 
standard 
Analytical 
Method 
UGT 
(general) 
4-Methylumbelliferone 10 
4-MU 
glucuronide 
0.05 Umbelliferone 
HPLC- 
Fluorescence 
UGT 1A1 Estradiol 30 
Estradiol 3-O-
glucuronide 
0.1 Dextromethorphan 
HPLC- 
Fluorescence 
UGT1A6 Acetaminophen 30 
Acetaminophen 
-glucuronide 
0.1 Caffeine HPLC-UV 
 
6.3 Results: 
 The overall intestinal UGT activity (4-MU glucuronidation) in rats was found to be 
higher in the obese group (Clint = 0.706 ± 0.02 ml/min/mg) as compared to the lean group 
(Clint = 0.113 ± 0.02 ml/min/mg) (p-value < 0.0001). UGT1a1 activity (estradiol 3-O-
glucuronidation) in rats was found to be higher in the obese group (Clint = 41.04 ± 12 
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µl/min/mg) than the lean group (Clint = 4.51 ± 0.6 µl/min/mg) (p-value = 0.035). UGT1a6 
and UGT1a7 activity (acetaminophen glucuronidation) in the rats was found to be higher 
in the obese group than the lean group (Clint = 0.29 ± 0.006 µl/min/mg vs. Clint = 0.06 ± 
0.01 µl/min/mg, p-value = 0.0002).  
 
6.4 Discussion: 
The results from our study indicate that there is increased activity in all tested UGTs 
in the small intestinal microsomes of the rats that were fed a HFD, with a significant 
increase in UGT activity in rats fed a HFD regardless of being obesity resistant (OR) or 
obesity prone (OP). This indicates that there is an overall diet effect on glucuronidation 
enzyme activity. This increase in enzyme activity may be due to increases in the 
expression of UGTs, as transcriptional regulators of UGTs have endogenous ligands 
whose levels may be altered with a HFD, which would lead to changes to expression and 
activity levels of UGTs. Transcriptional regulators of UGT expression include the ligand 
activated nuclear receptors Farsenoid X receptor (FXR), peroxisome proliferator-
activated receptor (PPARα), and nuclear factor (erythroid-derived 2)-like 2 (Nrf2). FXR 
activation is possibly increased in animals fed a HFD; as unsaturated fatty acids and bile 
acids are ligands for FXR and a HFD has been shown activate FXR likely due to 
enhanced enterohepatic flux of bile acids during HFD consumption.153 Fatty acids are 
also ligands for PPARα, which may have increased activation due to a HFD increasing 
fatty acid levels in the blood. For example, Patsouris and others showed that certain 
CYPs in rats were upregulated due to PPARα activation by lipids from a HFD.154 A HFD 
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has been shown to increase oxidative stress and cytokine production in the small 
intestine, and these increases in oxidative stress due to a HFD also increases Nrf2 
activation, which may lead to changes in the expression of UGTs.151  
The OR rats fed a HFD were not significantly heavier than the OR rats fed a LFD, but 
still exhibited increased UGT activity, which indicates that the change in UGT activity is 
diet-mediated and not obesity/weight-mediated. The OR rats also had higher overall 
clearance when compared to OP rats fed the same diet, which indicates that there may be 
genetic differences in the expression of UGTs between the two groups. More research 
must be done in order to determine if the resistance to obesity is correlated with the 
expression and activity of UGTs and how those two are related. In conclusion, our study 
shows that there are diet-mediated differences in UGT activity and that there are no 
weight/obesity-mediated differences. Because the effect of diet and obesity were studied 
only in a select few UGT isoforms, future studies should include other UGT isoforms in 
these models of obesity to determine if the increases in UGT activity reported in this 
study also apply to other isoforms. 
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Figure 6.1 
 
  4-methylumbelliferone  
Status Vmax (nmol/min/mg)   Km (µM)    CLint (mL/min/mg)  
OP 64 ± 2 
a
 582 ± 82 
a
 0.11 ± 0.01 
a
 
OP + HFD 240 ± 7 
b
 340 ± 15 
a
 0.71 ± 0.01 
b
 
OR 132 ± 6 
c
 433 ± 36 
a
 0.31 ± 0.01 
c
 
OR + HFD 454 ± 4 
d
 315 ± 8 
a
 1.44 ± 0.03 
d
 
 n=3 for each group 
Values with different letters in each column indicate a p-value ≤ 0.05, while values with 
the same letter are not significantly different from each other.
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Figure 6.2 
 
  Estradiol 
Status Vmax (nmol/min/mg)   Km (µM)    CLint (µL/min/mg)  
OP 0.213 ± 0.03 
a
 47 ± 3 
a
 4.5 ± 0.6 
a
 
OP + HFD 1.28 ± 0.2 
b
 34 ± 16 
a
 41.0 ± 12 
b
 
OR 0.629 ± 0.05 
c
 47 ± 14 
a
 13.9 ± 3 
c
 
OR + HFD 10.6 ± 2 
d
 106 ± 40 
a
 103 ± 14 
d
 
n=3 for each group 
Values with different letters in each column indicate a p-value ≤ 0.05, while values with 
the same letter are not significantly different from each other.
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Figure 6.3 
 
 
n=3 for each group 
Values with different letters in each column indicate a p-value ≤ 0.05, while values with 
the same letter are not significantly different from each other. 
  Acetaminophen 
Status Vmax (nmol/min/mg)   Km (mM)  CLint (µL/min/mg)  
OP 0.072 ± 0.002 
a
 1.2 ± .1 
a
 0.063 ± 0.008 
a
 
OP + HFD 2.8 ± 0.1 
b
 9.6 ± 0.5 
b
 0.29 ± 0.004 
b
 
OR 0.39 ± 0.02 
c
 3.7 ± 0.5 
c
 0.11 ± 0.01 
c
 
OR + HFD 14.5 ± 1 
d
 9.2 ± 1 
b
 1.6 ± 0.08 
d
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Conclusion 
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The purpose of this thesis was to examine the effect of obesity and high fat diet on 
cardiovascular risk factors (e.g. xanthine oxidase activity and uric acid formation) and on 
small intestinal drug metabolism.  In chapter II we developed an assay to measure the 
production of 7-hydroxy-lumazine to serve as more sensitive and accurate measure of 
plasma xanthine oxidase activity. This lumazine assay was then used to study xanthine 
oxidase as a risk factor for cardiovascular disease in obese children compared to normal-
weight children (chapter III), and this assay was also utilized to study xanthine oxidase 
activity in obese adolescents before and after weight loss to determine xanthine oxidase’s 
role in mediating changes in blood pressure due to weight loss (chapter IV). In order to 
study the effects of obesity and high fat diet on small intestinal drug metabolism, UGT 
activity was probed in a rat model of diet-induced obesity (chapter VI). 
 Using the lumazine assay that was developed to study the effect of obesity on 
cardiovascular risk and xanthine oxidase activity, it was discovered that plasma xanthine 
oxidase activity was increased in obese children. This increase in plasma xanthine 
oxidase activity was associated with BMI z-score and waist circumference, but was not 
associated with blood pressure. Therefore, in addition to the production of uric acid by 
xanthine oxidase, plasma uric acid levels and uric acid excretion was also measured in a 
follow-up study looking at the effects of weight loss in obese adolescents. Weight loss 
via meal replacement therapy led to decreases in both uric acid production and excretion, 
but no significant change in plasma levels. The change in diet in these subjects is 
hypothesized to be a factor in the decrease in xanthine oxidase activity. Plasma xanthine 
oxidase activity was also examined in adolescents that lost weight via bariatric surgery. 
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In the subjects with bariatric surgery, plasma xanthine oxidase activity was not 
significantly changed. The conflicting changes in xanthine oxidase activity between the 
weight loss methods may be explained by differing changes in the gut microbiota of the 
subjects; with the gut microbiota changing to produce less LPS in subjects losing weight 
via meal replacement therapy, and the gut microbiota changing to produce more LPS in 
subjects that lost weight via bariatric surgery. The changes in gut microbiota due to 
dietary fat content may also be responsible for the changes in intestinal UGT activity that 
is seen in our animal models of obesity. Increases in UGT activity were observed in both 
obesity resistant and obesity prone rats when they were fed a high fat diet, even though 
the obesity resistant rats didn’t gain a significant amount of weight when fed a high fat 
diet.  
In conclusion, a high fat diet and obesity lead to increases in xanthine oxidase 
activity and small intestinal UGT activity. The increase in xanthine oxidase activity due 
to obesity is not enough to predict changes in blood pressure, which makes it a poor 
measure of cardiovascular risk. The increases in small intestinal UGT activity due to 
obesity and high fat diet would lead to increased first pass metabolism, and may 
contribute to certain drugs, that are metabolized by UGTs, having lower efficacy in an 
obese population. The changes in xanthine oxidase activity and intestinal UGT activity 
due to obesity may  be due to changes to diets and gut microbiota. High fat diets have 
been shown to alter the gut microbiota and increase plasma LPS levels, and in our animal 
models it was shown to alter UGT activity even in obesity resistant rats that were not 
obese. Therefore, a high fat diet and not obesity may be responsible for both the changes 
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in xanthine oxidase and UGT activities, and future studies on obesity and CVD risk or 
alterations in drug metabolizing enzymes should focus on monitoring diets and changes 
to the gut microbiota. Records of dietary fat intake, LPS levels in the plasma/blood, and 
the composition of the gut microbiota should all be studied in future studies, as these may 
be the keys to understanding the physiological mechanism of the changes in CVD risk 
and activity of drug metabolizing enzymes due to obesity and high fat diets. 
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